Podcasts about Bayer

In der heutigen Folge sprechen die Finanzjournalisten Anja Ettel und Holger Zschäpitz über drohenden Ärger für Moderna, einen Kurskracher bei MongoDB und fiese Japan-Vibes. Außerdem geht es um Moderna, BioNTech, Novavax, Pfizer, GSK, MongoDB, Cleanspark, Coinbase, Robinhood, Strategy, Bitcoin, Ether, Bayer, Synopsis, Nvidia und The Magnum Ice Cream Company. Die aktuelle "Alles auf Aktien"-Umfrage findet Ihr unter: https://www.umfrageonline.com/c/mh9uebwm Wir freuen uns an Feedback über aaa@welt.de. Noch mehr "Alles auf Aktien" findet Ihr bei WELTplus und Apple Podcasts – inklusive aller Artikel der Hosts und AAA-Newsletter.[ Hier bei WELT.](https://www.welt.de/podcasts/alles-auf-aktien/plus247399208/Boersen-Podcast-AAA-Bonus-Folgen-Jede-Woche-noch-mehr-Antworten-auf-Eure-Boersen-Fragen.html.) [Hier] (https://open.spotify.com/playlist/6zxjyJpTMunyYCY6F7vHK1?si=8f6cTnkEQnmSrlMU8Vo6uQ) findest Du die Samstagsfolgen Klassiker-Playlist auf Spotify! Disclaimer: Die im Podcast besprochenen Aktien und Fonds stellen keine spezifischen Kauf- oder Anlage-Empfehlungen dar. Die Moderatoren und der Verlag haften nicht für etwaige Verluste, die aufgrund der Umsetzung der Gedanken oder Ideen entstehen. Hörtipps: Für alle, die noch mehr wissen wollen: Holger Zschäpitz können Sie jede Woche im Finanz- und Wirtschaftspodcast "Deffner&Zschäpitz" hören. +++ Werbung +++ Du möchtest mehr über unsere Werbepartner erfahren? [**Hier findest du alle Infos & Rabatte!**](https://linktr.ee/alles_auf_aktien) Impressum: https://www.welt.de/services/article7893735/Impressum.html Datenschutz: https://www.welt.de/services/article157550705/Datenschutzerklaerung-WELT-DIGITAL.html

Het Duitse argofarmabedrijf Bayer wordt al jaren achtervolgd door zaken rondom het onkruidbestrijdingsmiddel Roundup, dat kanker zou veroorzaken. Bayer krijgt nu steun van de Amerikaans regering in een zaak bij het Hoogerrechtshof. Volgens de regering zou een uitspraak van het hof dat Bayer in het ongelijkstelt de mogelijkheid bieden om op wetenschap gebaseerde oordelen van het Amerikaanse Environmental Protection Agency (EPA) ter discussie te stellen. De EPA al meerdere keren vastgsteld dat het middel waarschijnlijk niet kankerverwekkend is voor mensen. Het aandeel Bayer noteert hierdoor vandaag de hoogste koers in twee jaar tijd.

Audio roundup of selected biopharma industry content from Scrip over the business week ended November 28, 2025. In this episode: 2027 Medicare price cuts likely not as large as CMS estimates; Zai Lab leads DLL3 lung cancer ADC race; Phase II failure for J&J's Alzheimer's asset posdinemab; Bayer's positive Phase III data for asundexian in stroke; and Pfizer/Astellas's Padcev's first big win in bladder cancer study. Story links: https://insights.citeline.com/scrip/podcasts/scrips-five-must-know-things/quick-listen-scrips-five-must-know-things-R4RCDF2RXVGVHPEX2WQ7A3JVKU/ This episode was produced with the help of AI text-to-voice and voice emulation tools. Playlist: soundcloud.com/citelinesounds/sets/scrips-five-must-know-things

Dans cette vidéo, nous plongeons dans l'un des transferts les plus attendus de l'été : Xabi Alonso au Real Madrid ! Après avoir fait des merveilles avec le Bayer Leverkusen, le Basque prend les rênes du club Merengue dans une période de transition difficile. Adieu Carlo Ancelotti et ses Ligues des Champions à répétition… Place à un nouvel entraîneur, avec un style résolument moderne, offensif et très tactique. Mais la question demeure : Xabi Alonso a-t-il les épaules pour mener le Real Madrid au sommet de l'Europe à nouveau ?Dans cette vidéo, on revient sur sa carrière de joueur, son ascension comme entraîneur, son passage au Bayer Leverkusen et l'impact de ses idées footballistiques. Comment va-t-il gérer l'hégémonie du PSG et faire face à l'énorme pression du Real Madrid ? Le 3-4-2-1 qu'il adore va-t-il trouver sa place dans un club aussi prestigieux ? Et surtout, pourra-t-il gérer les egos des superstars comme Kylian Mbappé ?Allez, vamos, on plonge dans l'analyse d'un des coachs les plus prometteurs de la planète football !N'oubliez pas de vous abonner pour ne rien rater de cette aventure et des prochaines vidéos sur les grands coachs et transferts du moment !Pourquoi le Real Madrid peut détruire la carrière de Xabi AlonsoChapitre 1 : Un joueur fait pour devenir entraîneur 01:34Chapitre 2 : Une révolution au Bayer 03:17Chapitre 3 : Un mariage de raison ? 11:03 ---------------------------------------N'oublie pas de t'abonner, de liker, de commenter et de partager cette vidéo. Toutes les remarques sont bonnes à prendre, je n'hésiterai pas à utiliser tes retours pour nos prochaines vidéos. Active les notifications si tu ne veux rien louper sur Colinterview. Suis-moi sur toutes les plateformes :Facebook : https://bit.ly/3cJXvhfYouTube : https://bit.ly/3lb1yI1Instagram : https://bit.ly/3CR4zTCTikTok : https://bit.ly/3LJoaLqSnapchat : https://bit.ly/3cM5jPgTwitter : https://bit.ly/3s1yl5SSuis Oh My Goal sur toutes les plateformes :YouTube - Histoires FC - Oh My Goal : https://bit.ly/33Zo4OxYouTube - Oh My Goal - Actu Foot : https://bit.ly/3aY5gQcYouTube - Qu'est-il arrivé ? - Oh My Goal : https://bit.ly/3M4VtsmYouTube - Oh My Goal - Le Meilleur du Football : https://bit.ly/3sJdi7iYouTube - Oh My Goal - France - Shorts : https://bit.ly/3JE2A92Facebook : https://bit.ly/3nyCb2LInstagram : https://bit.ly/2S5jpEoTwitter : https://bit.ly/2Qyds2FTikTok : https://bit.ly/3xx8QKHOh My Goal : L'Hebdo | Snapchat : https://bit.ly/3xsREGd---------------------------------------© Oh My Goal

Nach Leverkusen ist vor Leverkusen. Wir blicken zurück auf den Auswärtssieg vom Samstag und versuchen daraus Schlüsse zu ziehen: Gelingt dem BVB das Weiterkommen im Pokal? Und welche Spieler bieten sich besonders an? Dazu holen wir U17-Trainer Marco Lehmann in den Podcast, denn seine Jungs haben am Wochenende beim VfL Bochum ein dickes Ausrufezeichen gesetzt. Als Tabellenführer in die Liga A. Stark! Darüber reden wir, in dieser Folge.

In der Podcast-Folge #147 von Klartext HR spricht Stefan Scheller mit Bernd Schmitz zum Thema „Skill-based hiring - Buzzword oder echte Veränderung?“. Skill-based Hiring ist in aller Munde. Dort, wo große Unternehmen häufig bereits eine durchgängige skillbasierte Employee Journey anstreben, ist vielen Mittelständlern noch gar nicht bewusst, wie sich Personalgewinnung mittels skill-based Hiring verändert und wie das aktuelle Whitepaper des Queb dabei unterstützen kann. Mit Bernd diskutiere ich unter anderem darüber, * was skill-based hiring ist * worin genau der Unterschied zum aktuellen Recruiting auf Basis von Abschlüssen und Zeugnissen besteht * welche Auswirkungen skill-based hiring auf die Recruitingprozesse hat * welche Skills die Recruitingverantwortlichen selbst dafür erwerben müssen * wo Recruiting-Organisationen anfangen können, die Transformation zu gestalten. * welche Rolle Technologie dabei spielt * welche Praxistipps er sonst noch dazu hat Ein spannender Talk als 15-Minuten-Impuls.
Klartext HR - Informieren. Inspirieren. Lernen.
Viel Spaß damit! Bernd Schmitz war über neun Jahre lang Vorstand im Bundesverband Queb und ist heute als Ehrenbeirat aktiv. In seiner vorherigen Rolle als Global Director Talent Acquisition Innovation bei Bayer hat er 2018 eine der ersten KI-basierten Skill-Matching-Plattformen weltweit eingeführt und global ausgerollt. Heute engagiert er sich als freier Kopf mit viel Herz für modernes Recruiting und begleitet unter anderem Queb-Mitgliedsunternehmen bei ihrer Transformation hin zu Skill-basierten HR-Strategien. Bernd gilt als einer der profiliertesten Vordenker für Skill-Based Hiring im deutschsprachigen Raum. Sein Herz schlägt für zukunftsfähige Recruiting-Konzepte, klare Worte – und gute Geschichten. >> LinkedIn-Profil von Bernd Schmitz: https://www.linkedin.com/in/berndschmitz >> Whitepaper-Download und Zusatzmaterial: https://www.queb.org/skills-based-hiring (deutsch) bzw. https://www.queb.org/skills-based-hiring-en (englisch) - beide Seiten enthalten das PDF, einen KI-Podcast sowie Lernvideos >> Hintergrund-Artikel zum Projekt: https://www.queb.org/blog/skills-based-hiring-das-whitepaper-das-hr-profis-jetzt-lesen-sollten >> weitere Folgen Klartext HR: https://persoblogger.de/klartext-hr >> Lernen Sie auch das Podcast-Format YOUR HR STAGE von Stefan Scheller kennen: https://persoblogger.de/your-hr-stage

Fluch beendet! Der BVB kann also doch noch gegen eine Top-Mannschaft gewinnen! Aber es gibt auch Redebedarf, gerade im Hinblick auf Serhou Guirassy. Beim Sieg über Bayer 04 Leverkusen leistet sich der Stürmer einen Aussetzer. Doch eine Szene ist fast noch besorgniserregender als die Reaktion auf seine Auswechslung. Muss Kovac durchgreifen? Und: Sportdirektor Sebastian Kehl kündigt Gespräche mit dem FC Chelsea an. Viel Spaß beim Hören! Der Podcast wird vermarktet durch die Ad Alliance. Die allgemeinen Datenschutzrichtlinien der Ad Alliance finden Sie unter [https://datenschutz.ad-alliance.de/podcast.html](https://datenschutz.ad-alliance.de/podcast.html) Die Ad Alliance verarbeitet im Zusammenhang mit dem Angebot die Podcasts-Daten. Wenn Sie der automatischen Übermittlung der Daten widersprechen wollen, klicken Sie hier: [https://datenschutz.ad-alliance.de/podcast.html](https://datenschutz.ad-alliance.de/podcast.html)

Today, we'll be tackling the future of prostate cancer care. We'll be reflecting on what prostate cancer care means in practice, how the way we think about the disease is shifting, and must continue to shift in the years ahead. Scientific advances have transformed treatment in recent years, yet the lived reality of prostate cancer still extends far beyond the clinic. The disease reshapes daily life, and may leave men and their families grappling with difficult choices about how best to manage it.  Dr. Güneş Taylor is joined by three key voices at the centre of this story, following the prostate cancer journey from diagnosis through to long-term management, and asking how patients and clinicians can work together to re-think what patient-centred care could mean in the years to come. This episode is brought to you in collaboration with Bayer, part of their Prostate Cancer Perspectives series.  PP-UN-ONC-GB-0168. November 2025 References Bray F, et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2024;74(3):229-263 (Prostate cancer is the second most common cancer in men and the fifth leading cause of cancer death worldwide) James D, et al. The Lancet Commission on prostate cancer: planning for the surge in cases. Lancet. 2024;403(10437):1683–1722 (Each year, around 1.5 million men are diagnosed and nearly 400,000 lose their lives to the disease.1 And the numbers are rising. Diagnoses are projected to double from 1.4 million annually in 2020 to 2.9 million by 2040) Siegel RL, et al. Cancer statistics, 2022. Ca Cancer J Clin. 2022;72:7–33 (In the U.S., the proportion of men diagnosed with advanced-stage prostate cancer has doubled in recent years, due to increasing incidence of advanced-stage disease and changing guidelines regarding the prostate specific antigen screening test, implemented in the U.S. in 2012) Dodkins J, et al. Geographic, socioeconomic and demographic inequalities in the incidence of metastatic prostate cancer at time of diagnosis in England: a population based evaluation. BMJ Oncology. 2025;4:e000643 (In England, nearly one in five men only receive a diagnosis once their cancer has spread) Calvo-Schimmel A, et al. Supportive care interventions and quality of life in advanced disease prostate cancer survivors: An integrative review of the literature. Can Oncol Nurs J. 2021;31(4):412-429 (Advanced prostate cancer is often associated with long-term challenges leading to greater levels of unmet needs in supportive care) Learn more about your ad choices. Visit podcastchoices.com/adchoices

Der Aktien-Schnelltest mit Oliver Kantimm ("Der Aktionärsbrief"). Hier im Beitrag gibt es die Podcast-Variante zur eigentlichen Sendung im Rahmen von BerneckerTV, Aufzeichnung des Hauptvideos am 27.11.2025). Schlaglichter:Bayer - Echte Chance auf TurnaroundWerblicher Hinweis auf Bernecker Black WeekABO Energy - Drastische GewinnwarnungLumentum Holdings - Erst mal heißgelaufenDiversified Energy - Mini-Bewertung plus XL-DividendenrenditeWir wünschen gewinnbringende Impulse mit diesem Beitrag.=======Bernecker Black Week - XXL-Erfahrung - XXL-Rabatte. Bitte schnell entscheiden. Aktionszeitraum gilt befristet bis 30.11.2025. Zur Aktionsseite:https://www.bernecker.info/black-week=======Lust auf noch mehr Sendungen im Bernecker.TV? Noch mehr unterschiedliche Experten? Infos zu Bernecker.TV:https://www.bernecker.info/bernecker-tv=======Anmeldung zum kostenlosen Experten-Newsletter der Bernecker-Redaktion über unsere Website:https://www.bernecker.info/newsletterDisclaimer:Diese Beitrag dient ausschließlich Informationszwecken und stellt keine Anlageberatung dar. Bitte beachten Sie, dass Investitionen in Aktien mit Risiken verbunden sind und Sie sich vor einer Anlageentscheidung umfassend informieren sollten.

Zwischen Villareal und Leverkusen ruht zwar der Ball. Themen gibt es bei Borussia Dortmund aber noch genug. Zum Beispiel eine heiße Diskussion, um die Sicherheit in deutschen Stadien. Außerdem muss man sich fragen, was aus Fabio Silva werden soll. Das und noch mehr besprechen wir heute bei BVB kompakt!

Tecnologia exclusiva da Bayer para controlar nematóides com mais precisão e proteger as raízes desde o início do ciclo

Bayer Crop Science continues to drive innovation in its corn and soybean new product pipelines. In this episode of Managing for Profit, Jamie Horton, DEKALB® brand manager, and Brittany Eubank, Asgrow brand manager, share a look at what's coming through Bayer's trait pipeline for future DEKALB® and Asgrow products. See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

Gabor Steingart präsentiert das Pioneer Briefing.

In der heutigen Folge sprechen die Finanzjournalisten Anja Ettel und Daniel Eckert über das Rekordhoch bei Alphabet, satte Gewinne bei Broadcom und einen Freudensprung bei Bayer. Außerdem geht es um Amazon, Meta, Tesla, Rheinmetall, Siemens Energy, Commerzbank, Deutsche Bank, Bristol-Myers Squibb, Johnson&Johnson, Zoom, Salesforce, UniGlobal (WKN: 849105) und Vanguard FTSE All-World thesaurierend (WKN: A2PKXG). Exklusiv für Euch als "Alles auf Aktien"-Hörer: Spart jetzt bis zu 83 Euro mit unserem BUSINESS INSIDER Black Friday Angebot. Erhaltet aktuelle News sowie Insights zur Finanzwelt und bleibt immer einen Schritt voraus https://www.businessinsider.de/abo/aaa/?tpcc=offsite_bi_aaa_podcast_bf_25 Die aktuelle "Alles auf Aktien"-Umfrage findet Ihr unter: https://www.umfrageonline.com/c/mh9uebwm Wir freuen uns an Feedback über aaa@welt.de. Noch mehr "Alles auf Aktien" findet Ihr bei WELTplus und Apple Podcasts – inklusive aller Artikel der Hosts und AAA-Newsletter.[ Hier bei WELT.](https://www.welt.de/podcasts/alles-auf-aktien/plus247399208/Boersen-Podcast-AAA-Bonus-Folgen-Jede-Woche-noch-mehr-Antworten-auf-Eure-Boersen-Fragen.html.) [Hier] (https://open.spotify.com/playlist/6zxjyJpTMunyYCY6F7vHK1?si=8f6cTnkEQnmSrlMU8Vo6uQ) findest Du die Samstagsfolgen Klassiker-Playlist auf Spotify! Disclaimer: Die im Podcast besprochenen Aktien und Fonds stellen keine spezifischen Kauf- oder Anlage-Empfehlungen dar. Die Moderatoren und der Verlag haften nicht für etwaige Verluste, die aufgrund der Umsetzung der Gedanken oder Ideen entstehen. Hörtipps: Für alle, die noch mehr wissen wollen: Holger Zschäpitz können Sie jede Woche im Finanz- und Wirtschaftspodcast "Deffner&Zschäpitz" hören. +++ Werbung +++ Du möchtest mehr über unsere Werbepartner erfahren? [**Hier findest du alle Infos & Rabatte!**](https://linktr.ee/alles_auf_aktien) Impressum: https://www.welt.de/services/article7893735/Impressum.html Datenschutz: https://www.welt.de/services/article157550705/Datenschutzerklaerung-WELT-DIGITAL.html

Ohne Aktien-Zugang ist's schwer? Starte jetzt bei unserem Partner Scalable Capital. Mit eigenem KI-Chatbot, der dir alle Fragen rund ums Investieren beantwortet. Alle weiteren Infos gibt's hier: scalable.capital/oaws. Novo Nordisk enttäuscht, Bayer überzeugt. Tesla setzt auf Chips, Amazon investiert weiter in KI-Infrastruktur. Grindr wird nicht privat, Alibaba hat viele KI-Nutzer, Julius Bär leidet weiter unter Signa und Oscar Health freut sich über Obamacare-Verlängerung. US-Modekonzern Gap (WKN: 863533) hat dasselbe Schicksal ereilt wie Abercrombie & Fitch oder American Eagle. Starker Aktienanstieg in den 2000er-Jahren, dann der Absturz. Doch Gap steckt jetzt in einer spannenden Transformation. Uli Hoeneß mag neben Fußball auch die Börse. In der Geburtstagsfolge vom OMR-Podcast hat er verraten, welche Aktien er zuletzt gekauft hat: Adidas (WKN: A1EWWW), BMW (WKN: 519000), Amazon (WKN: 906866) und Qualcomm (WKN: 883121) Diesen Podcast vom 25.11.2025, 3:00 Uhr stellt dir die Podstars GmbH (Noah Leidinger) zur Verfügung.

Send us a textGood morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. Today, we're diving into a series of impactful events and breakthroughs that are shaping patient care and drug development.The U.S. Food and Drug Administration recently granted early approval for a combination therapy using Padcev and Keytruda for the perioperative treatment of bladder cancer, a decision made months ahead of schedule. This approval represents a significant advancement in the therapeutic landscape for this type of cancer, offering new hope to patients who have had limited treatment options. The combination of these two therapies underscores the growing trend of integrating multiple mechanisms of action to tackle complex diseases like cancer more effectively. It also highlights the potential of combination therapies to provide enhanced clinical benefits by leveraging different therapeutic targets.In another notable development, Merck's partner Kelun announced successful Phase 3 trial results for an antibody-drug conjugate combined with Keytruda in treating PD-L1-positive non-small cell lung cancer (NSCLC). The trial results demonstrated statistically significant improvements in progression-free survival compared to Keytruda alone. This finding reinforces the expanding role of antibody-drug conjugates in oncology and emphasizes the importance of biomarker-driven therapies in personalizing cancer treatment. These advancements reflect a broader industry shift towards precision medicine, which aims to improve patient outcomes by tailoring treatments based on individual patient profiles.Meanwhile, Novo Nordisk experienced setbacks as its shares fell nearly 9% following two unsuccessful Phase 3 trials of semaglutide for Alzheimer's disease. Despite these disappointing results, this outcome highlights the persistent challenges and complexities inherent in developing therapies for neurodegenerative diseases—areas where unmet needs remain substantial. The market's reaction reflects investor sensitivity to clinical trial outcomes, particularly in high-stakes areas like Alzheimer's where breakthroughs are eagerly anticipated.Switching gears to AstraZeneca, the company is making a strategic move by expanding its manufacturing capabilities with a $2 billion investment in Maryland. This expansion reflects an ongoing trend among pharmaceutical companies to enhance their production infrastructure, driven by increasing demand for biologics and complex therapeutics. Such investments are crucial for supporting large-scale production needs and ensuring robust supply chains that are essential for meeting global health demands.In regulatory news, a collective letter from biotech CEOs addressed to FDA director Marty Makary has raised concerns about regulatory stability in the U.S., with 82% of biopharma respondents expressing apprehension over the FDA's ability to function predictably. This plea underscores how regulatory volatility can hinder innovation and emphasizes the importance of consistent policies that support long-term research and development efforts.In clinical trial updates, Bayer's oral FXIa inhibitor asundexian has shown promise in reducing stroke risk during Phase 3 trials. These findings revive interest in FXIa inhibitors as potentially blockbuster drugs after previous setbacks in this class. This development illustrates ongoing efforts to identify novel anticoagulant therapies that balance efficacy and safety, offering new hope for improved therapeutic options.Now turning our attention to Johnson & Johnson's recent setback with their anti-tau antibody posdinemab in a phase 2 trial targeting Alzheimer's disease. The trial was unable to demonstrate a significant slowing of clinical decline, leading JSupport the show

Een winnaar en een verliezer, allebei uit de farmasector: Bayer en Novo Nordisk. Met huisanalist Jef Poortmans. In Trends podcasts vind je alle podcasts van Trends en Trends Z, netjes geordend volgens publicatie.  De redactie van Trends brengt u verschillende podcasts over wat onze wereld en maatschappij beheerst.  Vanuit diverse invalshoeken en met een uitgesproken focus op economie en ondernemingen, op business, personal finance en beleggen.  Onafhankelijk, relevant, telkens constructief en toekomstgericht.  Hosted by Simplecast, an AdsWizz company. See https://pcm.adswizz.com for information about our collection and use of personal data for advertising.

Spezialausgabe des Heiko-Thieme-Clubs: Peter Heinrich und Andreas Groß melden sich aus Frankfurt - direkt nach Euro Finance Week und dem Eigenkapitalforum. Heiko Thieme zieht die große geopolitische Linie: China bleibt für ihn klar Diktatur und trotzdem unverzichtbarer Partner. Die Internationalisierung des Renminbi und der Aufstieg der BRICS-Staaten lassen die Dollar-Dominanz bröckeln. Europa wirkt in seinem Urteil dagegen reformmüde: Ohne Bankenunion und echte Mehrheitsentscheidungen droht der schleichende Bedeutungsverlust - auch wenn es mit Nebenwerten wie Deutz spannende Profiteure des KI-getriebenen Infrastruktur- und Strombooms gibt. Beim DAX sieht er nach der Korrektur realistische Chancen auf eine Weihnachtsrallye, ob neue Rekorde fallen, lässt er jedoch bewusst offen. Bitcoin bleibt für ihn fundamental "wertlos" und taugt nur als kleine Beimischung im Depot. Konkrete Aktiennamen nennt er ebenfalls: defensive Dauerläufer wie Procter & Gamble und Nestlé, Turnaround-Hoffnung Bayer, Qualitätswert SAP sowie spekulative Biotech-Titel wie BioNTech und Moderna.

Die Champions League steht wieder an! Der BVB trifft am Dienstag auf Villarreal, Leverkusen darf bei Manchester City ran. Während es bei den Dortmundern Diskussionen über einen Spruch von Trainer Niko Kovac gibt, fallen bei Bayer zahlreiche Profis aus. Außerdem Thema: Bastian Schweinsteiger, der laut Uli Hoeneß einen Posten bei den Bayern ablehnte. _Betonter Text_- [Instagram](https://www.instagram.com/stammplatz.pod/) - Stammplatz-Handy: 015165587282 - E-Mail: stammplatz@bild.de - Adresse: Stammplatz, André Albers, Kilian Gaffrey und Niklas Heising, Axel-Springer-Straße 65, 10888 Berlin Der tägliche Fußball-Podcast mit André Albers, Kilian Gaffrey und Niklas Heising! Stammplatz erscheint jeden Tag, wirklich JEDEN Tag! Wer hier zuhört, gibt beim Thema Fußball immer den Ton an!

In der heutigen Folge sprechen die Finanzjournalisten Daniel Eckert und Lea Oetjen über einen Volltreffer von Schalke 04, eine verhängnisvolle Meta-Studie und herbe Rückschläge für Defense-Tech-Unternehmen. Außerdem geht es um Siemens Energy, Rheinmetall, Hensoldt, Renk, Strategy, Bayer, Vanguard FTSE All-World (WKN: A1JX52), Vanguard FTSE All-World (WKN: A2PKXG), Vanguard Global Aggregate Bond ETF (WKN: A2PJZJ), iShares Polen (WKN: A1H5UP). Sichert euch mit diesem Link jetzt WELTplus zum AAA-Vorteilspreis – für mehr Tiefe, mehr Finanzen und mehr Vermögen.www.welt.de/aaablackfriday Die aktuelle "Alles auf Aktien"-Umfrage findet Ihr unter: https://www.umfrageonline.com/c/mh9uebwm Wir freuen uns an Feedback über aaa@welt.de. Noch mehr "Alles auf Aktien" findet Ihr bei WELTplus und Apple Podcasts – inklusive aller Artikel der Hosts und AAA-Newsletter.[ Hier bei WELT.](https://www.welt.de/podcasts/alles-auf-aktien/plus247399208/Boersen-Podcast-AAA-Bonus-Folgen-Jede-Woche-noch-mehr-Antworten-auf-Eure-Boersen-Fragen.html.) [Hier] (https://open.spotify.com/playlist/6zxjyJpTMunyYCY6F7vHK1?si=8f6cTnkEQnmSrlMU8Vo6uQ) findest Du die Samstagsfolgen Klassiker-Playlist auf Spotify! Disclaimer: Die im Podcast besprochenen Aktien und Fonds stellen keine spezifischen Kauf- oder Anlage-Empfehlungen dar. Die Moderatoren und der Verlag haften nicht für etwaige Verluste, die aufgrund der Umsetzung der Gedanken oder Ideen entstehen. Hörtipps: Für alle, die noch mehr wissen wollen: Holger Zschäpitz können Sie jede Woche im Finanz- und Wirtschaftspodcast "Deffner&Zschäpitz" hören. +++ Werbung +++ Du möchtest mehr über unsere Werbepartner erfahren? [**Hier findest du alle Infos & Rabatte!**](https://linktr.ee/alles_auf_aktien) Impressum: https://www.welt.de/services/article7893735/Impressum.html Datenschutz: https://www.welt.de/services/article157550705/Datenschutzerklaerung-WELT-DIGITAL.html

At Marketecture Live, Alexis Gossard, Senior Manager of Media Strategy at Bayer, and Lisa Perez, General Manager for Pain/Cardio/Derm and Nutritionals, discuss the recent shift in strategy behind the One A Day brand. They outline how the team revisited brand fundamentals, updated the visual identity, refined audience-specific messaging, and adjusted the media approach across video, social, retail, and emerging channels. The conversation offers a clear look at the decision-making process, cross-functional collaboration, and early learnings from the brand's updated direction. Takeaways Bayer Consumer Health aims to reach more households. The mission is described as the road to billions. A dedicated team focuses on media outcomes. Every media plan outcome is linked to new brand initiatives. The strategy involves analyzing various channels for effectiveness. Household penetration is a key performance indicator. The company is committed to understanding market dynamics. Media planning is crucial for brand growth. The focus is on measurable outcomes in marketing. Bayer is leveraging data to inform its strategies. Chapters 00:10 Opening & Brand Challenge 00:50 Brand Overview & Market Realities 01:06 Audience Complexity & Strategic Shift 03:06 Rebuilding the Brand Foundation 04:39 Visual Identity & Packaging Refresh 06:32 Cross-Functional Collaboration 08:45 Turning Insights Into Media Strategy 09:48 Awareness Strategy & Football Integration 13:23 Advanced Targeting, AI, and Geo-Clustering 18:38 What's Next & Q&A Highlights Learn more about your ad choices. Visit megaphone.fm/adchoices

Ponemos el foco en valores como Rheinmetall, Leonardo, Dassault, Bayer, Siemens Energy, BHP y Ubisoft. Con Pablo Garcia, director general de Divacons-Alphavalue.

Chelsea Spieker präsentiert das Pioneer Briefing.

Zapraszamy do fascynującego uniwersum, w którym spotkamy obecnego prezesa PZPN-u, kapłankę ze świątyni Abu Simbel i polskich gangsterów.*➤ ODWIEDŹ NASZ SKLEP: https://pozdrawiam.net/kategoria-produktu/podcastex/➤ WESPRZYJ PODCASTEX: https://patronite.pl/podcastex➤ POSTAW NAM KAWĘ: https://suppi.pl/podcastex________________Zapytania biznesowe: kontakt@podcastex.pl

Send us a textGood morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. Today, we delve into a landscape marked by significant scientific advancements, regulatory approvals, and strategic shifts that are reshaping the industry.Starting with Regeneron, the company's ophthalmic drug Eylea HD has recently secured two FDA approvals. These endorsements not only grant a new indication but also introduce a more flexible dosing regimen. This positions Eylea HD competitively against Roche's Vabysmo, highlighting the importance of regulatory navigation and strategic positioning in the pharmaceutical sector. These approvals come after extensive negotiations with both the FDA and third-party manufacturers, emphasizing the intricate processes involved in bringing a drug to market.In oncology, Bayer has achieved an accelerated FDA approval for Hyrnuo, a treatment targeting HER2-mutated non-small cell lung cancer. This move allows Bayer to challenge Boehringer Ingelheim's Hernexeos, underscoring the fiercely competitive nature of the oncology market. Such advancements are driven by innovative treatments that address specific genetic mutations in cancer patients, reflecting a broader trend towards precision medicine.Meanwhile, Moderna is investing heavily in mRNA production capabilities with a new $140 million facility in Norwood, Massachusetts. This development underscores Moderna's commitment to mRNA technology, which gained significant attention during the COVID-19 pandemic. The facility aims to establish robust domestic manufacturing infrastructures to mitigate supply chain vulnerabilities—a critical move considering recent global disruptions.Novartis is also making headlines with its plans for a flagship production hub in North Carolina. This expansion is expected to create 700 jobs and expand its manufacturing footprint by 700,000 square feet, highlighting Novartis's strategic emphasis on scaling up operations to meet growing demands and enhance production efficiency.In another strategic collaboration, Antheia has joined forces with Teva's TAPI division to enhance the commercialization prospects for its biosynthetic pipeline. This alliance marks a significant step toward advancing biologically derived pharmaceuticals, promising to revolutionize drug production through more sustainable and scalable alternatives to traditional chemical synthesis.On the regulatory front, Merck has received broad EU approval for a subcutaneous formulation of Keytruda. This development could significantly expand Keytruda's market reach across Europe, demonstrating how regulatory agility can extend drug lifecycles and maximize therapeutic impact across diverse patient populations.Compliance challenges remain prevalent, as illustrated by Pfizer and Tris Pharma's settlement of allegations related to ADHD medication Quillivant's quality control issues for $41.5 million. This case highlights ongoing efforts to ensure stringent quality standards within pharmaceutical manufacturing processes.Abbott is expanding its diagnostics portfolio through a $23 billion acquisition of Exact Sciences, known for its Cologuard colorectal cancer test. This acquisition indicates a strategic shift towards enhancing diagnostic capabilities alongside therapeutic offerings—a trend increasingly evident in holistic healthcare solutions.GSK is embarking on a $7 billion collaboration with biotechs Quotient and Profound through Flagship Pioneering. This partnership aims to leverage novel protein and genomic technologies to drive innovation in drug discovery and development, illustrating the industry's focus on integrating advanced biotechnological insights into traditional pharmaceutical frameworks.These developments collectively underscore crSupport the show

Richie is joined by Hedley Rees. Hedley is a pharmaceutical supply-chain specialist with decades of experience in the industry. He's held senior roles at companies including Bayer and Johnson & Johnson. These days he runs PharmaFlow, a consultancy firm advising on drug manufacturing and logistics. Back in 2020 he raised serious concerns about the COVID-19 vaccine supply chain and the total absence of regulatory oversight during the rollout of the jabs. Hedley knew the jabs would cause widespread harm. Despite a concerted campaign of censorship, Hedley never gave up. Since 2024, he has been writing to the UK regulator - MHRA - and demanding answers. Follow and support Hedley here:https://substack.com/@hedleyrees1https://www.facebook.com/hedley.rees.967

This episode covers: Cardiology This Week: A concise summary of recent studies 'ChatGPT, MD?' - Large Language Models at the Bedside Management decisions in myocarditis Statistics Made Easy: Mendelian randomisation Host: Emer Joyce Guests: Carlos Aguiar, Folkert Asselbergs, Massimo Imazio Want to watch that episode? Go to: https://esc365.escardio.org/event/2179 Want to watch that extended interview on 'ChatGPT, MD?': Large Language Models at the Bedside? Go to: https://esc365.escardio.org/event/2179?resource=interview Disclaimer: ESC TV Today is supported by Bristol Myers Squibb and Novartis through an independent funding. The programme has not been influenced in any way by its funding partners. This programme is intended for health care professionals only and is to be used for educational purposes. The European Society of Cardiology (ESC) does not aim to promote medicinal products nor devices. Any views or opinions expressed are the presenters' own and do not reflect the views of the ESC. The ESC is not liable for any translated content of this video. The English language always prevails. Declarations of interests: Stephan Achenbach, Folkert Asselbergs, Yasmina Bououdina, Massimo Imazio, Emer Joyce, and Nicolle Kraenkel have declared to have no potential conflicts of interest to report. Carlos Aguiar has declared to have potential conflicts of interest to report: personal fees for consultancy and/or speaker fees from Abbott, AbbVie, Alnylam, Amgen, AstraZeneca, Bayer, BiAL, Boehringer-Ingelheim, Daiichi-Sankyo, Ferrer, Gilead, GSK, Lilly, Novartis, Pfizer, Sanofi, Servier, Takeda, Tecnimede. John-Paul Carpenter has declared to have potential conflicts of interest to report: stockholder MyCardium AI. Davide Capodanno has declared to have potential conflicts of interest to report: Bristol Myers Squibb, Daiichi Sankyo, Sanofi Aventis, Novo Nordisk, Terumo. Konstantinos Koskinas has declared to have potential conflicts of interest to report: honoraria from MSD, Daiichi Sankyo, Sanofi. Steffen Petersen has declared to have potential conflicts of interest to report: consultancy for Circle Cardiovascular Imaging Inc. Calgary, Alberta, Canada.  Emma Svennberg has declared to have potential conflicts of interest to report: Abbott, Astra Zeneca, Bayer, Bristol-Myers, Squibb-Pfizer, Johnson & Johnson.

Host: Emer Joyce Guest: Folkert Asselbergs Want to watch that episode? Go to: https://esc365.escardio.org/event/2179 Want to watch that extended interview on 'ChatGPT, MD?': Large Language Models at the Bedside? Go to: https://esc365.escardio.org/event/2179?resource=interview Disclaimer: ESC TV Today is supported by Bristol Myers Squibb and Novartis through an independent funding. The programme has not been influenced in any way by its funding partners. This programme is intended for health care professionals only and is to be used for educational purposes. The European Society of Cardiology (ESC) does not aim to promote medicinal products nor devices. Any views or opinions expressed are the presenters' own and do not reflect the views of the ESC. The ESC is not liable for any translated content of this video. The English language always prevails.  Declarations of interests: Stephan Achenbach, Folkert Asselbergs, Yasmina Bououdina, Emer Joyce, and Nicolle Kraenkel have declared to have no potential conflicts of interest to report. Carlos Aguiar has declared to have potential conflicts of interest to report: personal fees for consultancy and/or speaker fees from Abbott, AbbVie, Alnylam, Amgen, AstraZeneca, Bayer, BiAL, Boehringer-Ingelheim, Daiichi-Sankyo, Ferrer, Gilead, GSK, Lilly, Novartis, Pfizer, Sanofi, Servier, Takeda, Tecnimede. John-Paul Carpenter has declared to have potential conflicts of interest to report: stockholder MyCardium AI. Davide Capodanno has declared to have potential conflicts of interest to report: Bristol Myers Squibb, Daiichi Sankyo, Sanofi Aventis, Novo Nordisk, Terumo. Konstantinos Koskinas has declared to have potential conflicts of interest to report: honoraria from MSD, Daiichi Sankyo, Sanofi. Steffen Petersen has declared to have potential conflicts of interest to report: consultancy for Circle Cardiovascular Imaging Inc. Calgary, Alberta, Canada. E mma Svennberg has declared to have potential conflicts of interest to report: Abbott, Astra Zeneca, Bayer, Bristol-Myers, Squibb-Pfizer, Johnson & Johnson. Abbott, Astra Zeneca, Bayer, Bristol-Myers, Squibb-Pfizer, Johnson & Johnson.

Medical Affairs Unscripted welcomes Dr. Jeff Humphrey—an experienced CMO with three decades across Bristol Myers Squibb, Pfizer, Bayer, Kyowa Kirin, and multiple biotechs—to discuss why the Target Product Profile (TPP) is the foundation of effective drug development. He shares a clear framework for "starting with the end in mind," from scientific fit and standards of care to regulatory precedent, investor expectations, and the smart use of AI. Humphrey also underscores the importance of working with patient-first KOLs and reminds listeners that poorly planned development can waste years of people's lives and millions of dollars.

En Belém, los delegados de la COP30 tienen plazo hasta el viernes para negociar un acuerdo ambicioso contra el cambio climático, pero la sombra del cabildeo vuelve a cernirse sobre la cumbre con la presencia de un número récord: 1.600 representantes del sector de los hidrocarburos. Informe de nuestro enviado especial a Bélem, Raphael Moran. El sector agrícola es responsable de al menos un tercio de las emisiones de CO₂ en el mundo. A pesar de ello, cientos de cabilderos de la agroindustria defienden sus intereses en los pasillos de la COP30 en Belém. A diez minutos del recinto de Naciones Unidas, donde delegados de todo el mundo negocian el futuro climático del planeta, transnacionales del sector agroindustrial como Bayer o el sindicato brasileño del agronegocio CNA se pintan de verde y prometen una agricultura sostenible mediante spots, charlas y degustaciones. Según el medio de investigación brasileño The Intercept, varias empresas implicadas en escándalos ambientales —como JBS, Vale o la transnacional del aluminio Hydro— patrocinan a medios brasileños a cambio de una cobertura favorable durante la COP30. Organizaciones de la sociedad civil denuncian la cantidad inédita de miembros de grupos de presión, en particular de los combustibles fósiles. "Hay 300 delegados que representan a las grandes industrias de la agricultura y la ganadería aquí en la COP30", señala Xananine Calvillo, activista indígena Ngiwa de México. "Esto representa un aumento del 14 % respecto a la conferencia del año pasado. Y muchos de ellos, el 25 %, participan en las negociaciones con acreditaciones expedidas por los Estados que representan. Es decir, están entrando a las negociaciones, algo que los pueblos indígenas no podemos hacer". ¿Quiénes les pagan?  Calvillo exige también más transparencia sobre los intereses de los participantes en las cumbres climáticas: "Para esto de los lobistas hay una campaña que busca esa transparencia, pidiendo que ellos digan quiénes son y por quiénes están siendo pagados". Naciones Unidas, organizadora de las cumbres climáticas, propone —pero no obliga— que los participantes de las COP indiquen su eventual afiliación a intereses corporativos. Esta declaratoria no incluye a los empresarios acreditados por delegaciones oficiales. Francia acreditó, por ejemplo, al presidente de la transnacional petrolera TotalEnergies. La sombra del cabildeo planea sobre las COP desde hace varios años. En 2018, un alto cargo de la petrolera Shell celebró que sus propuestas para la creación de mercados de carbono figuraran en el artículo 6 del Acuerdo de París.

Bayer is expected to have a 2027/28 market introduction for Vyconic soybeans in the U.S. and Canada. In this episode of Managing for Profit, Tyler Uhe, U.S. soy portfolio lead at Bayer Crop Science, discusses the latest soybean trait innovation and what it means for farmers.See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

In this episode, Dr. Ashwin Mehta joins us to talk about how AI is quietly changing the way we think, learn, and make decisions. Drawing from his global career in pharma, government, and consulting, from building digital learning systems in West Africa to leading AI strategy at Bayer — Ashwin shares why he's dedicated his work to keeping the “human” at the center of technology.We explore how trust in AI can evolve from confidence to dependency, what “agentic AI” really means for the future of work, and the mental habits we risk losing as machines start thinking for us. Ashwin also reflects on what he still refuses to let AI handle, and why maintaining human judgment may be the ultimate competitive edge in an increasingly automated world.Dr. Ashwin Mehta helps organizations adopt AI in ways that put people first. With a PhD in digital learning adoption and over 20 years across pharma, government, consulting, and international health, he focuses on the intersection of technology, human capital, and transformation. His experience includes leading AI-enabled learning at Bayer, advising enterprises and governments at Deloitte, and building digital training systems in West Africa during crises.As founder of Mehtadology, Ashwin designs AI strategies that align technology with human potential, covering topics from large language models to intelligent automation while addressing readiness, infrastructure, and culture. His research and writing offer insights on adaptive learning, AI ROI, and the cognitive impacts of delegating decisions to machines.

Send us a textGood morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. Today, we delve into a host of transformative events reshaping the landscape, from strategic acquisitions and funding infusions to regulatory maneuvers and scientific breakthroughs.Johnson & Johnson has taken a decisive step in its oncology strategy with the $3 billion acquisition of Halda's cell death technology. This acquisition, focusing on the "hold and kill" bifunctional small molecule platform, is poised to enhance J&J's prostate cancer pipeline significantly. It underscores J&J's commitment to expanding its oncology portfolio through innovative platforms designed to improve therapeutic outcomes. The move highlights a broader industry trend toward personalized medicine and targeted cancer therapies, which are becoming pivotal in improving patient care.In another domain of cancer treatment, Nuvalent has unveiled promising Phase 1/2 data for its candidate neladalkib, which could position the company as a formidable competitor to Pfizer's established lung cancer drug, Lorbrena. The promising data might expedite regulatory discussions with the FDA, potentially leading to an accelerated approval process. This development illustrates the competitive landscape in oncology, where firms strive to introduce novel therapies with improved efficacy and safety profiles.The field of antibody-drug conjugates (ADCs) is also experiencing significant advancements. A San Diego-based biotech has secured $120 million in funding to develop a best-in-class ADC formula, with support from Merck & Co. This initiative aims to refine the precision and efficacy of ADCs by delivering cytotoxic agents directly to cancer cells while minimizing collateral damage to healthy tissues. Such innovations are crucial as they represent a new frontier in targeted cancer therapy.In terms of financial activities, Artios Pharma's successful $115 million Series D funding round is set to bolster its clinical efforts in exploring DNA damage response inhibitors for cancer treatment. These inhibitors target cancer cells' ability to repair DNA damage, holding potential for more effective therapies against resistant cancer types. Meanwhile, Sofinnova Partners' €650 million raise for biotech and medtech investments amid a volatile economic environment underscores continued investor confidence in life sciences despite market uncertainties.Bayer is making strategic moves in China by opening an incubator in Beijing. This facility will host local biopharma companies such as Suzhou Puhe Biopharma and Beijing Youngen Technology, fostering innovation and collaboration within China's burgeoning biotech landscape. Such initiatives reflect global efforts to leverage regional strengths and foster cross-border collaborations.On the operational side, Nxera Pharma is restructuring its workforce by laying off 15% of its staff as part of a strategic pivot towards profitability. This decision mirrors broader industry trends where companies refocus resources on core projects to streamline operations and enhance financial stability.A recent study has highlighted the impact of NIH grant cuts on clinical trials across the United States. Over 383 trials involving more than 74,000 patients have been disrupted due to funding terminations under the current administration. This situation raises concerns about the sustainability of clinical research funding and its implications for ongoing medical advancements.Jazz Pharmaceuticals has reported practice-changing Phase 3 results for its HER2-targeted drug Ziihera for gastroesophageal adenocarcinoma. These findings reaffirm Jazz's confidence in positioning Ziihera as a preferred first-line treatment option for HER2-positive cancers, poSupport the show

Bayer is reshaping its pharmaceutical business with a new operating model designed to enhance collaboration and bring research & development and commercialization closer together. In a recent episode of The Top Line podcast, Bayer executives Christine Roth, Executive Vice President and Head of Global Product Strategy and Commercialization, and Dr. Yesmean Wahdan, Head of Medical Affairs for the United States and North America, discussed how the company’s Dynamic Shared Ownership framework is driving faster innovation and helping accelerate the development of new therapies for patients. The model removes traditional hierarchies, empowers cross-functional teams and encourages real-time collaboration across departments. Roth and Wahdan said the approach has already shortened regulatory timelines, reduced resource use and helped deliver treatments to patients sooner. By embedding commercial insights early in the research process, Bayer teams can anticipate market needs and focus on the greatest areas of unmet medical demand. The leaders said the company’s collaborative culture keeps patient benefit at the center of decision-making. To learn more about how Bayer’s model is transforming its pipeline, listen to the full episode of The Top Line. See more from Bayer’s Christine Roth and Dr. Yesmean Wahdan on their LinkedIn profiles below: Christine: https://www.linkedin.com/in/christine-roth-34b07b18/ Yesmean: https://www.linkedin.com/in/yesmean-h-wahdan-md-71409b199/ See omnystudio.com/listener for privacy information.

Are multivitamins bad for you? How could that be? In this video, I'll share the truth about the multivitamin scam. Find out about the vitamins you should never take, supplements that don't work, and the harmful ingredients in your supplements. 0:00 Introduction: Multivitamins truth0:19 Harmful ingredients in supplements 1:45 Synthetic vs. natural vitamins 3:38 Do multivitamins really work?9:32 Natural vitamins and minerals11:17 Fake vitamins exposed! Many multivitamins are made with the cheapest, synthetic ingredients which could be doing more harm than good.The first ingredient in many multivitamins is often calcium carbonate, which is limestone! The first ingredient usually makes up the majority of the product. Magnesium oxide, another common ingredient, is very cheap and has the lowest absorption rate compared to other forms of magnesium. The term “natural” isn't regulated, so ingredients derived from sources such as petroleum and coal tar can be labeled as natural. In nature, vitamins don't exist alone; they are combined with other nutrients and cofactors, which are often missing when you take synthetic vitamins. Biochemistry can not work without cofactors. Although there are nutrients that are difficult to obtain in sufficient amounts from food, that doesn't mean they should be replaced with synthetic multivitamins.Maltodextrin is commonly used as a filler in vitamins and minerals. It's a highly refined industrial starch, classified as a complex carbohydrate, and spikes blood sugar more than sugar. Ascorbic acid is a synthetic part of the vitamin C complex. Approximately 90% is made in China from GMO corn and sulfuric acid. Many people have a genetic issue converting cyanocobalamin, a synthetic form of B12, and folic acid, a synthetic form of B9, into their active forms. This can cause negative side effects in 40% of the population.Almost all of the popular multivitamins are owned by Big Pharma, Big Food, Big Chemical, or large investment groups. For example, Centrum Silver is owned by Pfizer, and One a Day is owned by Bayer. Nature Made is owned by the same company that sells Abilify!Dr. Eric Berg DC Bio:Dr. Berg, age 60, is a chiropractor who specializes in Healthy Ketosis & Intermittent Fasting. He is the Director of Dr. Berg Nutritionals and author of the best-selling book The Healthy Keto Plan. He no longer practices, but focuses on health education through social media.Disclaimer: Dr. Eric Berg received his Doctor of Chiropractic degree from Palmer College of Chiropractic in 1988. His use of “doctor” or “Dr.” in relation to himself solely refers to that degree. Dr. Berg is a licensed chiropractor in Virginia, California, and Louisiana, but he no longer practices chiropractic in any state and does not see patients, so he can focus on educating people as a full-time activity, yet he maintains an active license. This video is for general informational purposes only. It should not be used to self-diagnose, and it is not a substitute for a medical exam, cure, treatment, diagnosis, prescription, or recommendation. It does not create a doctor-patient relationship between Dr. Berg and you. You should not make any change in your health regimen or diet before first consulting a physician and obtaining a medical exam, diagnosis, and recommendation. Always seek the advice of a physician or other qualified health provider with any questions you may have regarding a medical condition.

It's In the News.. a look at the top headlines and stories in the diabetes community. This week's top stories: It's World Diabetes Day and we have a LOT of news to get to! Daily oral insulin tested to prevent T1D, mothers and sons and a T1D link, stem cell updates, Tandem Android news, Omnipod's workplace campaign and more! Find out how to submit your Community Commercial Find out more about Moms' Night Out  Please visit our Sponsors & Partners - they help make the show possible! Learn more about Gvoke Glucagon Gvoke HypoPen® (glucagon injection): Glucagon Injection For Very Low Blood Sugar (gvokeglucagon.com) Omnipod - Simplify Life Learn about Dexcom   Check out VIVI Cap to protect your insulin from extreme temperatures The best way to keep up with Stacey and the show is by signing up for our weekly newsletter: Sign up for our newsletter here Here's where to find us: Facebook (Group) Facebook (Page) Instagram Twitter Check out Stacey's books! Learn more about everything at our home page www.diabetes-connections.com  Reach out with questions or comments: info@diabetes-connections.com Episode transcription with links:   Hello and welcome to Diabetes Connections In the News! I'm Stacey Simms and every other Friday I bring you a short episode with the top diabetes stories and headlines happening now. It's world diabetes day! It is marked every year on 14 November, the birthday of Sir Frederick Banting, who co-discovered insulin along with Charles Best in 1922.   WDD was created in 1991 by International Diabetes Federation (IDF) and the World Health Organization and became an official United Nations Day in 2006 with the passage of United Nations Resolution 61/225. There will be a ton of stuff in your feeds today and that's great! I'm going to keep this to a pretty normal in the news episode.. although I do have my own World Diabetes Day announcement – I want YOUR community commercials. You could have an ad for your event or your blog or your project right here! There's a post on the website explaining it all and I'll come back at the end of the episode and tell you more. XX The Primary Oral Insulin Trial (POInT) is the first large-scale clinical trial to test whether giving at-risk children daily oral insulin could prevent or delay type 1 diabetes (T1D). Conducted by researchers from Helmholtz Munich and the Technical University of Munich across five European countries, the study enrolled more than 1,000 children with a genetic risk for T1D. Results published in The Lancet show that while oral insulin did not prevent the development of islet autoantibodies—an early sign of diabetes—it was safe and well tolerated. Importantly, researchers found that some children who received oral insulin developed diabetes more slowly than those given a placebo, suggesting potential protective effects in certain genetic subgroups.   Further analysis revealed that the response to treatment depended on the child's insulin gene variant. Children with genetic versions that raise diabetes risk appeared to benefit, showing delayed onset of the disease, while those without the risk variant did not. These findings point toward a future of personalized prevention, where genetic screening could help identify which children might benefit most from oral insulin. Researchers will continue following the participants until age 12 to assess long-term effects. The study marks a major milestone in decades of diabetes prevention research, highlighting both the promise and complexity of developing tailored, early interventions against type 1 diabetes. XX Joint US-Chinese research looking at generating new beta cells from stomach cells. Upon turning on the "genetic switch," the human stomach cells were converted to insulin-secreting cells within the mice and resembled pancreatic beta cells with respect to gene and protein expression. Encouragingly, when those experiments were done with diabetic mice, insulin secreted from the transformed human cells helped control blood sugar levels and ameliorated diabetes. The scientists hope that a similar approach can be taken to convert cells from a patient's own stomach into insulin-secreting cells directly within the body. Importantly, additional studies are needed to address if this approach is safe and effective to be used in patients. https://www.technologynetworks.com/cell-science/news/human-stomach-cells-tweaked-to-make-insulin-406694 XX A new study in Nature Metabolism may help explain why children born to mothers with type 1 diabetes are less likely to develop the disease early in life compared to those whose fathers or siblings have it. Researchers looked at nearly 2,000 mothers and their children and found that  kids whose moms have type 1 diabetes show changes in their DNA that may actually help protect them. These aren't genetic mutations, but epigenetic changes — chemical tags that turn certain genes on or off. The study found these changes in genes tied to the immune system and type 1 diabetes risk, suggesting that a mother's condition during pregnancy can shape her child's immune response in a protective way. Scientists identified more than 500 areas of DNA where these changes occurred, many in regions that control how the body's immune system works. Most of the changes appeared to calm down the kind of overactive immune response that leads to type 1 diabetes. Researchers even created a "methylation score" to help measure this protective effect. They say the next step is to confirm these results in more diverse groups and figure out exactly how these DNA changes help prevent early diabetes. https://www.news-medical.net/news/20251110/Maternal-type-1-diabetes-may-protect-children-from-developing-the-disease.aspx XX A new study from Karolinska Institutet and Stockholm University reveals that sons born to mothers with type 1 diabetes may develop early vascular dysfunction—independently of metabolic health. The finding may help shape future strategies to prevent cardiovascular disease early in life.     Children of women with type 1 diabetes are known to be at increased risk of developing cardiovascular diseases. This new study, published in Cell Reports Medicine, is the first to show that the risk is linked to early dysfunction in blood vessel cells in sons, even before any metabolic issues arise. The team is now investigating the long-term effects of maternal diabetes, with a particular focus on why sons seem to be affected earlier than daughters. https://medicalxpress.com/news/2025-11-sons-mothers-diabetes-early-vascular.html XX A new study presented at Kidney Week 2025 has shown that the drug finn-uh-near-own  a nonsteroidal mineralocorticoid-receptor antagonist, significantly reduced albuminuria—a key marker of kidney damage—in people with type 1 diabetes (T1D) and chronic kidney disease (CKD). This is the first major breakthrough for this population in more than 30 years. Researchers found that patients taking finerenone saw a 25% average reduction in albuminuria compared to placebo, an improvement that suggests a lower long-term risk for dialysis or kidney transplant. The phase 3 FINE-ONE trial involved 242 adults with T1D and CKD, and results showed benefits as early as three months. The drug was generally well tolerated, with side effects similar to those seen in patients with type 2 diabetes, though mild hyperkalemia (high potassium levels) was slightly more common. Experts say the findings could change the way doctors treat kidney complications in type 1 diabetes, an area that hasn't seen new therapies since the early 1990s. Currently, treatment options rely on blood pressure and blood sugar management, along with renin-angiotensin system (RAS) inhibitors. Finerenone, which is already approved for type 2 diabetes-related CKD, targets overactivation of a receptor that drives kidney damage. Based on these results, Bayer plans to seek FDA approval in 2026 for use in people with T1D and CKD. Researchers and clinicians alike are calling the study "groundbreaking," noting that it opens the door to future research on how finerenone might not just slow kidney decline—but possibly prevent it altogether. https://www.medscape.com/viewarticle/finerenone-offers-hope-kidney-disease-type-1-diabetes-2025a1000uzi?form=login   XX This week, Tandem Diabetes Care (Nasdaq:TNDM) announced a major milestone for its Mobi miniature durable insulin pump system. San Diego-based Tandem revealed that it received FDA approval for the Android version of its Mobi mobile app. Clearance brings Mobi — which the company describes as the world's smallest, durable automated insulin delivery system — to more users. The pump, which pairs with Tandem's Control-IQ+ algorithm, previously worked with iOS software.   Tandem — one of the largest diabetes tech companies in the world — expects to begin a limited rollout next month, followed by full commercial availability in early 2026. This marks the latest milestone for the company, which continues to expand its offerings and widen its reach within the diabetes patient population.   We had a great interview with Tandem on our previous episode, but as I said at the time, it was coming before their earnings call. So here's an update: The company plans to submit the tubeless mobi to the fda before the end of this year.. possible approval and shipping date is hoped for by middle of 2026. Trials for their fully closed loop next-generation algorithm which we tlkaed abou ton the show should be launched in 2026 The Sigi patch pump will be developed and launched as a next-generation version of the Mobi Great job by Dr. David ? Ahn – he posted on IG after getting a message from tandem CEO John Sheridan? 1. First, the Tandem X3 *is* still absolutely in development, contrary to my speculation In yesterday's video. As many of you appropriately pointed out, there is definitely a market for a 300 unit pump, a pump with a screen, and a pump that does not require smartphone control. So from our brief chat, the sense I got that is that the X3 would be more of a refresh of the X2 with newer components, such as a USB-C connector and better memory, rather than a total redesign from the ground up. In terms of timing, all I could get was that it was "not too far distant in the future," which could mean anything I guess, but at least it's still on the way! 2. Next up, he also reassured me that they are working closely with Dexcom to support the G7 15 Day sensor within the next few months. I suspected as much, but it's always good to hear confirmation. 3. Lastly, he did confirm that Tandem is far along in developing a Caregiver/Follow app to allow the remote viewing of glucose and insulin data from a Tandem pump. He explained that it will be based on Sugarmate, the popular diabetes data dashboard app that Tandem acquired back in Jun 2020. While I don't know if every feature will make it into the Tandem caregiver app, Sugarmate is well-liked for its highly customizable dashboard and highly configurable alerts. Sugarmate even has the option to send a text message or phone call for urgent lows. Regardless, a true follow/Caregiver app will be welcomed with open arms by all caregivers and Tandem users who use Libre 3 Plus. https://time.com/7318020/worlds-top-healthtech-companies-2025/ XX Senseonics submits Eversense 365 – their year long implantable CGM for a CE mark, European Approval and expect to launch there soon. Eversense will be integrated with the sequel twist pump – again I'm hearing soon but no timeline. Intersting to note that one year inseration was approved in the US just about a year ago, so the first patients will be having their CGMs changed out – for the first time – pretty soon. https://www.drugdeliverybusiness.com/senseonics-q2-2025-sales-beat-ce-mark/ XX A confusing study out of Rutgers - these researcher say  metformin reduces some of the key benefits normally gained from regular physical activity. These include improvements in blood vessel health, physical fitness, and the body's ability to regulate blood sugar. Since 2006, doctors have typically encouraged patients with elevated blood sugar levels to combine metformin with exercise, expecting that the two proven treatments would produce stronger results together. However, the new research suggests this may not be the case. In this study, Exercise alone improved vascular insulin sensitivity, meaning blood vessels responded better to insulin and allowed more blood flow to muscles. This matters because insulin's ability to open blood vessels helps shuttle glucose out of the bloodstream and into tissues, lowering blood sugar after meals. But when metformin was added, the improvements shrank. The drug also diminished gains in aerobic fitness and reduced the positive effects on inflammation and fasting glucose. The findings don't mean people should stop taking metformin or exercising, Malin said. Instead, it raises urgent questions for doctors about how the two treatments can be combined and the need for close monitoring. Malin hopes future research will uncover strategies that preserve the benefits of both. https://scitechdaily.com/popular-diabetes-drug-metformin-may-cancel-out-exercise-benefits-study-warns/ XX XX https://www.medtechdive.com/news/Revvity-Sanofi-diabetes-test-Kihealth-seed-round/802133/   XX Dexcom recalled an Android app for its G6 glucose sensor due to a software problem that could cause the app to terminate unexpectedly. The issue could cause users to miss alarms, alerts or notifications related to estimated glucose values, according to a Food and Drug Administration database entry posted Oct. 30. The glucose sensor and the app are still available, but Dexcom required users to update the app to a new version. Dexcom began the recall on Aug. 28. The FDA designated the event as a Class 1 recall, the most serious kind. Dexcom sent a notification to customers in September about the software bug, which applies to version 1.15 of the G6 Android app. To use the app, customers must update it to a new version, according to the entry. https://www.medtechdive.com/news/dexcom-recall-g6-cgm-app/804630/ XX https://www.medscape.com/viewarticle/automated-insulin-delivery-boosts-glycemic-control-youth-2025a1000ub3 XX Tidepool partners with smart ring maker OURA.. press release says: to support a groundbreaking dataset intended to be broadly available for diabetes research, with participation limited to individuals who opt in through Tidepool.         Tidepool will pair biometric data from Oura Ring – sleep, activity, heart rate, temperature trends, and menstrual cycles – with diabetes device data, including continuous glucose monitors (CGMs) and insulin pumps. The result will provide researchers with an unprecedented dataset to accelerate the development of new clinical guidelines, next-generation diabetes technology, and personalized care models.   Recruitment is expected to launch in early 2026 through an IRB-approved study. By opting in to this study, participants consent to sharing their data with Tidepool's Big Data Donation Project, where data is de-identified and, with participant consent, shared with academics, researchers, and industry innovators to accelerate diabetes research. https://aijourn.com/tidepool-collaborates-with-oura-to-advance-inclusive-diabetes-research-through-wearables/ XX Eli Lilly launches two new clinical trials for baricitinib. These phase 3 trials will investigate whether the drug can delay T1D onset or progression and will open for recruitment soon. Baricitinib has the potential to extend the "honeymoon period" of T1D, meaning that it could preserve remaining insulin-producing beta cells earlier in disease progression. More beta cells mean better blood sugar management—and potentially reduced long-term complications. JAK inhibitors, including baricitinib, are already FDA-approved for other autoimmune diseases, such as rheumatoid arthritis, alopecia, and more. JAK signaling pathways are associated with overactive immune responses, so blocking this pathway may turn down the immune response. The phase 2 Breakthrough T1D-funded BANDIT study was key in showing that this drug is safe and effective in T1D. Importantly, baricitinib is a once-daily oral pill—meaning its use is simple and easy.   https://www.breakthrought1d.org/news-and-updates/two-new-trials-baricitinib-to-delay-t1d/ XX   Insulet is taking diabetes awareness into the workplace. Having found 79% of people with diabetes have faced bias or misunderstanding at work, the medtech giant is rolling out a range of resources intended to trigger changes in how workplaces approach the condition. Lots going on for Diabetes Awareness month.. some notables.. Insulet's "The Day Diabetes Showed up to Work" campaign. based on a survey of almost 10,000 people 79% of people with diabetes have faced bias or misunderstanding at work,.   Almost 90% of people with diabetes surveyed reported experiencing barriers at work due to their condition, and more than 40% of people with diabetes and caregivers said they have workplace-related anxiety tied to the metabolic disease. Around one-quarter of respondents reported fears that diabetes could limit opportunities or lead to workplace discrimination and judgment, and a similar proportion of people said they conceal their condition. https://www.fiercepharma.com/marketing/widespread-workplace-challenges-people-diabetes-spark-insulet-campaign XX New directive issued by the Trump administration could mean people seeking visas to live in the U.S. might be rejected if they have certain medical conditions, including diabetes or obesity.   The guidance, issued in a cable the State Department sent to embassy and consular officials and examined by KFF Health News, directs visa officers to deem applicants ineligible to enter the U.S. for several new reasons, including age or the likelihood they might rely on public benefits.   The guidance says that such people could become a "public charge" — a potential drain on U.S. resources — because of their health issues or age.   The cable's language appears at odds with the Foreign Affairs Manual, the State Department's own handbook, which says that visa officers cannot reject an application based on "what if" scenarios, Wheeler said.   The guidance directs visa officers to develop "their own thoughts about what could lead to some sort of medical emergency or sort of medical costs in the future," he said. "That's troubling because they're not medically trained, they have no experience in this area, and they shouldn't be making projections based on their own personal knowledge or bias."   Immigrants already undergo a medical exam by a physician who's been approved by a U.S. embassy. https://www.npr.org/2025/11/12/nx-s1-5606348/immigrants-visas-health-conditions-trump-guidance XX SAN DIEGO---Nov. 14, 2025—DexCom, Inc. (NASDAQ: DXCM), the global leader in glucose biosensing, today unveiled 16 new diabetes advocates to represent people living with diabetes globally as part of Dexcom's World Diabetes Day campaign. The advocates – ranging from ages six to 68, spanning various types of diabetes, and hailing from four continents and five countries – were selected from 1,000 open call submissions based on their experiences advocating for people with diabetes in their communities. While each person's experience with diabetes is unique, they share a common passion for advocacy – and use of Dexcom's glucose biosensing technology. "Through advocacy, I strive to show others, especially children and newly diagnosed patients, that diabetes is not a limitation but an opportunity to grow stronger, inspire resilience and pursue ambitious goals," said Maria Alejandra Jove Valerio, one of Dexcom's new advocates. "What began as a diagnosis at age seven has grown into a lifelong mission to uplift others." This effort represents the first time Dexcom has sourced voices from the broader diabetes community specifically for its World Diabetes Day campaign, reinforcing Dexcom's history of and commitment to giving real people with diabetes a platform to share their story on a global stage. Through engaging, editorial-style portraits and deeply personal stories, the campaign highlights each advocate's personal experience with diabetes, what misconceptions about diabetes they'd like to dispel and how they want to inspire others with diabetes to discover what they're made of. To prepare for the spotlight, the group of advocates met in Los Angeles for a World Diabetes Day photoshoot which included a surprise visit from Grammy-nominated artist, actor, producer and Dexcom Warrior Lance Bass and author, producer, actress and Stelo*Ambassador Retta. This visit offered the advocates an opportunity to exchange stories and personal perspectives on the meaning of diabetes advocacy and how they live it each day. Behind the lens at the shoot was another member of the diabetes community—photographer Tommy Lundberg who lives with Type 1 diabetes. "Directing this photoshoot was nothing short of inspiring. Each of these advocates has a unique an XX On what would have been the 100th birthday of its visionary founder Alfred E. Mann, MannKind Corporation (Nasdaq: MNKD), in partnership with Alfred E. Mann Charities and The Diabetes Link, announced the launch of the Centennial Al Mann Scholarship. The new program will distribute $100,000 in scholarship funds to support at least 10 young adult students living with diabetes as they pursue higher education in life sciences.   Launched in Diabetes Awareness Month, the scholarship program honors Alfred E. Mann's enduring legacy of innovation, philanthropy, and his lifelong commitment to improving the quality of human life through medical advancement. Deeply passionate about giving back, Mr. Mann believed that his success should continue to serve humanity long after his passing, a belief that lives on through this initiative.   Each scholarship recipient will be awarded up to $10,000, distributed in annual installments of $2,500 throughout the course of their studies. Depending on the length of their degree program, recipients may receive between two and four installments (up to the full $10,000 per student). The first awards will be made for the 2026 academic year.   "Al Mann dedicated his life to helping people with serious medical conditions live longer, healthier lives. This scholarship is a reflection of that spirit," said Michael Castagna, PharmD, Chief Executive Officer of MannKind Corporation. "By supporting students living with diabetes who are pursuing careers in the life sciences and adjacent fields, we're honoring Al's legacy and investing in the future of innovation and care. This program is about giving back to the community we serve and empowering the next generation to carry forward Al's mission of making a meaningful difference in people's lives."   Alfred E. Mann Charities and MannKind will partner with The Diabetes Link to launch the program to serve young adults (aged 18-22) living with either type 1 or type 2 diabetes with their higher education goals. Those eligible will include incoming freshmen and current students pursuing 2- or 4-year degrees. The application window will open in early 2026, and for those interested in receiving notifications, an early interest form is available. More information about the scholarship will be shared on thediabeteslink.org.   "We're honored to partner with MannKind to expand access to higher education for young adults with diabetes," said Manuel Hernández, Chief Executive Officer of The Diabetes Link. "At a time when the cost of college continues to rise, this scholarship helps ease the financial burden and carries forward the spirit of Al Mann, whose vision and legacy continue to inspire us."   Mr. Mann was MannKind's Chairman of the Board from 2001 until his passing in February 2016 and served as Chief Executive Officer from November 2003 until January 2015. Driven by a desire to improve lives and fill unmet medical needs, for more than six decades he founded 17 companies and developed breakthrough medical devices, including insulin pumps, cochlear implants, cardiac pacemakers and retinal prostheses. In 1997, Mr. Mann saw the potential of a dry powder insulin formulation to change the way diabetes is treated and invested nearly $1 billion to help bring Afrezza® (insulin human) Inhalation Powder to market.   About MannKind MannKind Corporation (Nasdaq: MNKD) is a biopharmaceutical company dedicated to transforming chronic disease care through innovative, patient-centric solutions. Focused on cardiometabolic and orphan lung diseases, we develop and commercialize treatments that address serious unmet medical needs, including diabetes, pulmonary hypertension, and fluid overload in heart failure and chronic kidney disease.   With deep expertise in drug-device combinations, MannKind aims to deliver therapies designed to fit seamlessly into daily life.   Learn more at mannkindcorp.com.   About Alfred E. Mann Charities, Inc. Alfred E. Mann Charities, Inc. became active in 2016, following the passing of the organization's benefactor, Alfred E. Mann. Throughout his life, Al was passionate about philanthropy and was dedicated to prolonging and improving the quality of human lives through innovation in the fields of healthcare and the use of medical devices. It was important to Al that his success and assets continue to better human lives even after his own passing.   Alfred E. Mann Charities, Inc. (formerly known as Alfred E. Mann Family Foundation) has similarly placed its primary focus on healthcare and medical innovation, as our organization believes this is where we can have the greatest impact on humanity and human health throughout the world. Alfred E. Mann Charities, Inc. is also dedicated to promoting arts, culture, education, and community development across Los Angeles and throughout the world in order to best serve people and this planet.   Learn more at aemanncharities.org.   About The Diabetes Link The Diabetes Link is the only national nonprofit organization dedicated to empowering young adults living with diabetes. Founded by and for young adults, The Link serves this community through peer support, leadership opportunities, and practical, evidence-based resources designed for real life. Its network of campus and community chapters, active online community, and robust Resource Hub help young adults navigate the transitions of early adulthood while managing diabetes. The organization envisions a future where every young adult living with diabetes has

In der heutigen Folge sprechen die Finanzjournalisten Anja Ettel und Philipp Vetter über Pfizers Abschied von Biontech, eine letzte Enttäuschung für Wirecard-Aktionäre und den Siemens-Absturz. Außerdem geht es um Tesla, Nvidia, Broadcom, Alphabet, Amazon, Cloudflare, Siemens Healthineers, Siemens Energy, Rolls-Royce, Airbus, Boeing, Volkswagen, Merck, Gilead, Johnson&Johnson, Eli Lilly, Bayer, Merck KGaA, Xtrackers MSCI World Health Care ETF (WKN: 113FD), VanEck Morningstar Developed Markets Dividend Leaders (WKN: A2JAHJ), iShares Stoxx Global Select Dividend 100 (WKN: A0F5U), Fidelity Emerging Markets Quality Income ETF (WKN: A2PQDRI), Invesco FTSE EM High Dividend Low Volatility ETF (WKN: A2AHZU) Invesco und den Euro Stoxx High Dividend Low Volatility (WKN: A2ABHF) . Hier findet ihr den BYD-Aktiensplit-Artikel von Lea: https://www.welt.de/wirtschaft/plus68a8494d5d3e123a945a783f/BYD-Aktiensplit-Was-Anleger-nach-dem-Steuer-Aerger-jetzt-wissen-muessen-und-tun-koennen.html Unter diesem Link könnt ihr euch kostenlos für die Masterclass anmelden: https://form.jotform.com/Product_Unit/masterclass-boersenweisheiten Wir freuen uns an Feedback über aaa@welt.de. Noch mehr "Alles auf Aktien" findet Ihr bei WELTplus und Apple Podcasts – inklusive aller Artikel der Hosts und AAA-Newsletter.[ Hier bei WELT.](https://www.welt.de/podcasts/alles-auf-aktien/plus247399208/Boersen-Podcast-AAA-Bonus-Folgen-Jede-Woche-noch-mehr-Antworten-auf-Eure-Boersen-Fragen.html.) [Hier] (https://open.spotify.com/playlist/6zxjyJpTMunyYCY6F7vHK1?si=8f6cTnkEQnmSrlMU8Vo6uQ) findest Du die Samstagsfolgen Klassiker-Playlist auf Spotify! Disclaimer: Die im Podcast besprochenen Aktien und Fonds stellen keine spezifischen Kauf- oder Anlage-Empfehlungen dar. Die Moderatoren und der Verlag haften nicht für etwaige Verluste, die aufgrund der Umsetzung der Gedanken oder Ideen entstehen. Hörtipps: Für alle, die noch mehr wissen wollen: Holger Zschäpitz können Sie jede Woche im Finanz- und Wirtschaftspodcast "Deffner&Zschäpitz" hören. +++ Werbung +++ Du möchtest mehr über unsere Werbepartner erfahren? [**Hier findest du alle Infos & Rabatte!**](https://linktr.ee/alles_auf_aktien) Impressum: https://www.welt.de/services/article7893735/Impressum.html Datenschutz: https://www.welt.de/services/article157550705/Datenschutzerklaerung-WELT-DIGITAL.html

En el Radar Empresarial, Capital Intereconomía ha puesto hoy el foco en Ubisoft, en un momento clave para la compañía por su proceso de recuperación operativa y su posición en la industria del videojuego. En el consultorio de Investing, Carlos González (Investing.com España) ha analizado el comportamiento de los principales índices en la recta final de la semana, con especial atención al Ibex 35, que encadena varios máximos históricos. También se ha evaluado el resultado de ACS, tanto desde el punto de vista fundamental como de valoración, y se han respondido preguntas de la audiencia sobre Inditex, Iberdrola, Bayer, Acciona, y compañías con potencial de crecimiento. Investing Pro ha aportado sus listas de valores infravalorados y sobrevalorados para identificar oportunidades y riesgos, especialmente entre las grandes tecnológicas a la espera de los resultados de NVIDIA la próxima semana. Incluso se ha recurrido a Warren AI para contrastar valoraciones. En el Foro de la Inversión, Pablo López Gil-Albarellos (Trade Republic) ha analizado tendencias de inversión y comportamiento del ahorrador europeo. La jornada ha cerrado con Cripto Capital, donde Enrique Palacios (Bit2Me) ha detallado la importancia de la autorización de la CNMV para que Bit2Me STX se transforme en agencia de valores, un avance clave para la institucionalización del sector cripto en España.

Bundesregierung einigt sich auf Reform des Wehrdienstes, Jugendliche ab Jahrgang 2008 müssen zur Musterung erscheinen, Brandbrief von Wirtschaftsverbänden über geplante Finanzierung der künftigen Renten, EU-Kommission lockert das 2024 beschlossene Lieferkettengesetz, Forschergruppe "Global Carbon Project" errechnet weltweit höchsten CO2-Ausstoß, Zehnter Jahrestag der Terroranschläge in Paris mit 130 Toten, WM-Qualifikation: Abschlusstraining der Fußball-Nationalmannschaft, Das Wetter Korrektur: Diese Sendung wurde nachträglich bearbeitet. In der 20 Uhr vom 13.11.2025 haben wir den Fußballspieler Jonathan Tah fälschlicherweise Bayer 04 Leverkusen zugeordnet. Er spielt seit dieser Saison aber bei Bayern München. Diesen Fehler haben wir korrigiert.

Bundesregierung einigt sich auf Reform des Wehrdienstes, Jugendliche ab Jahrgang 2008 müssen zur Musterung erscheinen, Brandbrief von Wirtschaftsverbänden über geplante Finanzierung der künftigen Renten, EU-Kommission lockert das 2024 beschlossene Lieferkettengesetz, Forschergruppe "Global Carbon Project" errechnet weltweit höchsten CO2-Ausstoß, Zehnter Jahrestag der Terroranschläge in Paris mit 130 Toten, WM-Qualifikation: Abschlusstraining der Fußball-Nationalmannschaft, Das Wetter Korrektur: Diese Sendung wurde nachträglich bearbeitet. In der 20 Uhr vom 13.11.2025 haben wir den Fußballspieler Jonathan Tah fälschlicherweise Bayer 04 Leverkusen zugeordnet. Er spielt seit dieser Saison aber bei Bayern München. Diesen Fehler haben wir korrigiert.

In der heutigen Folge sprechen die Finanzjournalisten Anja Ettel und Philipp Vetter über Zoff bei den Wirtschaftsweisen, das nächste Palantir und den unendlichen Glyphosat-Fluch bei Bayer. Außerdem geht es um BigBear.ai, Cisco, Xtrackers II Euro Corporates ETF (WKN: DBX0AC), SPDR Bloomberg SASB Euro Corporate Bond ETF (WKN: A2PF0W), Siemens, L'Oréal, ishares Global Corp Bond ETF (WK: A0RGEP), Apple, J&J, Vanguard EUR Corporate Bond UCITS ETF (WKN A2PA8G), Amazon, Alphabet, Nvidia, DWS, Amundi, BlackRock, Commerzbank, Deutsche Bank, ING und BNP Paribas. Unter diesem Link könnt ihr euch kostenlos für die Masterclass anmelden: https://form.jotform.com/Product_Unit/masterclass-boersenweisheiten Wir freuen uns über Feedback an aaa@welt.de. Noch mehr "Alles auf Aktien" findet Ihr bei WELTplus und Apple Podcasts – inklusive aller Artikel der Hosts und AAA-Newsletter.[ Hier bei WELT.](https://www.welt.de/podcasts/alles-auf-aktien/plus247399208/Boersen-Podcast-AAA-Bonus-Folgen-Jede-Woche-noch-mehr-Antworten-auf-Eure-Boersen-Fragen.html.) [Hier] (https://open.spotify.com/playlist/6zxjyJpTMunyYCY6F7vHK1?si=8f6cTnkEQnmSrlMU8Vo6uQ) findest Du die Samstagsfolgen Klassiker-Playlist auf Spotify! Disclaimer: Die im Podcast besprochenen Aktien und Fonds stellen keine spezifischen Kauf- oder Anlage-Empfehlungen dar. Die Moderatoren und der Verlag haften nicht für etwaige Verluste, die aufgrund der Umsetzung der Gedanken oder Ideen entstehen. Hörtipps: Für alle, die noch mehr wissen wollen: Holger Zschäpitz können Sie jede Woche im Finanz- und Wirtschaftspodcast "Deffner&Zschäpitz" hören. +++ Werbung +++ Du möchtest mehr über unsere Werbepartner erfahren? [**Hier findest du alle Infos & Rabatte!**](https://linktr.ee/alles_auf_aktien) Impressum: https://www.welt.de/services/article7893735/Impressum.html Datenschutz: https://www.welt.de/services/article157550705/Datenschutzerklaerung-WELT-DIGITAL.html

Beleggers keken deze week uit naar de beleggersdag van Adyen, waarop het bedrijf de nieuwe doelstellingen presenteerde. "Niet héél ambitieus, die doelstellingen", vindt Thomas Pellegrom van ABN Amro. Toch begrijpt hij de positieve reactie van beleggers. "Het zijn nog steeds mooie marges, en Adyen doet het heel goed als je het vergelijkt met Fiserv. Die Amerikaanse concurrent verloor de helft van z'n waarde op beroerde cijfers." Joost van Leenders van Van Lanschot Kempen zit op hetzelfde spoor. "Ik denk dat de doelstellingen bewust conservatief zijn gehouden, om tegenvallers uit te sluiten. Met een koerswinstverhouding van 26 is het aandeel niet extreem gewaardeerd en het is een hele sterke speler in de betalingssector. Over het sentiment zijn beide experts positief, al lijkt de markt op dit moment wat te consolideren. Een AI-bubbel die op springen staat, zo ver is het nog niet en de topspelers in die sector zijn zeer winstgevend Dat niet alleen, ze geven de indices nog steeds de grootste impuls. Verder in de podcast aandacht voor de overname van NIBC door ABN Amro en de cijfers van die laatste. Ook de cijfers van onder andere TKH, Bayer en Aegon worden besproken. De luisteraarsvragen komen aan bod en de experts geven hun tips. Joost tipt deze keer een Amerikaanse bank, Thomas gaat voor een tracker met de ISIN-code IE00B579F325. Geniet van de podcast! Let op: alleen het eerste deel is vrij te beluisteren. Wil je de hele podcast (luisteraarsvragen en tips) horen, wordt dan Premium lid van BeursTalk. Dat kost slechts 9,95 per maand, 99 euro voor een heel jaar. Abonneren kan hier! VanEck ETF’s (advertorial) Deze week is ook weer het tweewekelijks gesprek te beluisteren met Martijn Rozemuller, ceo van VanEckETF’s, de partner van BeursTalk. Met Martijn bespreek ik deze week de praktijk van securities lending. Securities lending komt er simpel gezegd op neer dat, in dit geval, de uitgever van een ETF de onderliggende aandelen uitleent. Uiteraard tegen een vergoeding, die deels terugvloeit naar de eigenaar van de ETF. Dat lijkt mooi, maar er zitten ook bezwaren aan. Get belangrijkste is wel dat er een zogenaamd tegenpartijrisico aan vast zit. Stel dat de lener in de problemen komt en de aandelen niet kan teruggeven, wat dan? We bespreken ook een andere vorm van tegenpartijrisico: de synthetische ETF. Daarbij koopt de uitgever van de ETF niet de aandelen van de index, maar sluit een overeenkomst met een tegenpartij die beloofd de performance van de index te leveren. Ook kier, zo legt Martijn helder uit, speelt natuurlijk het risico dat de financiële tegenpartij in de problemen kan komen. Ter geruststelling: VanEck Europe heeft alleen fysieke ETF's en leent ook geen aandelen uit. Geniet van de podcast! De gepresenteerde informatie door VanEck Asset Management B.V. en de aan haar verbonden en gelieerde bedrijven (samen "VanEck") is enkel bedoeld voor informatie en advertentie doeleinden aan Nederlandse beleggers die Nederlands belastingplichtig zijn en vormt geen juridisch, fiscaal of beleggingsadvies. VanEck Asset Management B.V. is een UCITS-beheerder. Loop geen onnodig risico. Lees de Essentiële Beleggersinformatie of het Essentiële-informatiedocument. Meer informatie? https://www.vaneck.com/nl/nl/ See omnystudio.com/listener for privacy information.

Unser Partner Scalable Capital ist der einzige Broker, den deine Familie zum Traden braucht. Bei Scalable Capital gibt's nämlich auch Kinderdepots. Alle weiteren Infos gibt's hier: scalable.capital/oaws. AMD will stärker wachsen, Infineon ist optimistisch und Foxconn verdient mehr als gedacht - der KI sei jeweils Dank. On wächst besonders stark in Asien, RWE überzeugt und Bayer spart gut. Ledger will an die Börse, Coinbase nicht kaufen und Circle enttäuscht. 70-Mrd.-$-Konzern AON (WKN: A2P2JR) verkauft nicht selbst Versicherungen, sondern vermittelt Kunden die passende Versicherung von anderen Firmen. Heißt: Risiko niedrig, Umsätze stabil. Ein Shortseller hat seit Ende 2024 gegen Strategy (WKN: 722713) gewettet. Jetzt hat er die Position geschlossen. Probleme hat der Konzern, der gerne eigene Aktien verkauft und Bitcoins kauft, trotzdem. Diesen Podcast vom 13.11.2025, 3:00 Uhr stellt dir die Podstars GmbH (Noah Leidinger) zur Verfügung.

In this episode, Kelly, known as Glyphosate Girl on Instagram, shares her profound experience and knowledge about glyphosate. The conversation begins with Kelly's personal narrative on facing multiple health issues, leading her to explore the adverse effects of glyphosate. The discussion encompasses the origins, widespread use, and dangerous impacts of glyphosate on human health and the environment. Furthermore, Kelly sheds light on Monsanto's controversial practices and the ongoing legal battles. She emphasizes the importance of regenerative agriculture as a solution to move away from reliance on such chemicals.     03:04 Introduction to Glyphosate 03:52 Personal Health Journey 07:05 Discovering Glyphosate's Impact 09:32 History and Use of Glyphosate 14:43 Glyphosate in Our Environment 24:24 Health Implications of Glyphosate 27:20 Legal Battles and Public Awareness 28:16 The EPA's Initial Findings on Glyphosate 29:28 Monsanto's Response and Manipulation 30:31 International Agency for Research on Cancer's Findings 32:05 EPA's Controversial Decision 32:43 Political and Regulatory Challenges 38:04 The Role of Regenerative Agriculture 41:56 Bayer's Acquisition and Legal Battles 43:26 Liability Shields and Legislative Efforts 44:55 Public Awareness and Personal Responsibility 51:38 The European Perspective on Glyphosate    

A crisp crash course on announcing your fundraise correctly, including:a good timeline for drafting, reviewing, and sending out the press releasehow to correctly manage stakeholder feedbackand how to maximize the benefits of the announcementThe guest you'll hear from today, Elisheva Marcus, and I met at the Deep Tech Momentum conference in Berlin and connected over nerding out about comms.Elisheva Marcus has an MSc in Biomedical Communication and brings expertise from the San Jose Mercury News, Ada Health, Bayer, and more. Since 2020, she has been the VP of Communications at Earlybird Venture Capital, supporting portfolio founders as a sparring partner. By the way, Earlybird Venture Capital was founded in 1997 and is among the most experienced venture investors in Europe, covering all development and growth stages from pre-seed to growth in industries like fintech, health tech, and deep tech.---LinksConnect with Elli:https://www.linkedin.com/in/elisheva-marcus/Check out Earlybird:https://earlybird.com/Connect with me:https://www.linkedin.com/in/schmidt-marina/Structure of a Strong Press Release or AnnouncementTitleUse active, direct language.Avoid buzzwords.Commit to a single, powerful title (no subtitle).Key Bullet PointsThree concise bullets summarizing the essential news.Designed for quick journalistic scanning.Represent the three to four main ideas the body will expand on.Header InformationInclude date and location.Opening ParagraphStart with a strong, engaging first sentence.Avoid generic or slow openings.Main BodyExpand on the bullet points in a clear, logical flow.Ensure coherence and story progression.Cover the who, what, where, when, and why.Include:Amount raised (with correct denomination)Impact and significanceThe team and why they're the right peopleA quote from leadership or a clientHow the funds will be used and why it's memorableClosing SectionEnd with a short About section or call to action.Provide contact or follow-up information.

In der heutigen Folge sprechen die Finanzjournalisten Anja Ettel und Philipp Vetter über Robotikfantasie bei Xpeng, die Weihnachtsüberraschung von FedEx und den Shutdown-Schub für Pharma. Außerdem geht es um Merck, Johnson&Johnson, Amgen, CoreWeave, Nvidia, Softbank, Micron, Oracle, Palantir, Merck KGaA, Siemens Healthineers, UPS, Bayer, Amazon, Alphabet, Microsoft, iShares Core MSCI World ETF (WKN: A0RPWH), Amundi MSCI All Country World ETF (WKN: LYX00C), Vanguard S&P 500 ETF (WKN: A1JX53), iShares Nasdaq 100 ETF (WKN: A0YEDL), Amundi Core Stoxx Europe 600 ETF (WKN: LYX0Q0), Xtrackers MSCI Japan ETF (WKN: DBX1MJ), iShares MSCI China ETF (WKN: A2PGQN), Xtrackers Artificial Intelligence & Big Data ETF (WKN: A2N6LC), Alphabet, Apple, Nvidia und Palantir, Euwax Gold II (WKN: EWG2LD), Xetra Gold (WKN: A0S9GB), Global X Infrastructure ETF (WKN: A40E7B), Vanguard FTSE All World (WKN: A2PKXG), SPDR MSCI All Country World ETF (WKN: A1JJTC), Xtrackers MSCI Emerging Markets ETF (WKN: A12GVR), Vanguard FTSE Emerging Markets ETF (WKN: A2PLTC), iShares EUR High Yield Corporate Bond (WKN: A2DUCZ) und PIMCO Euro Short-Term High Yield Corporate Bond (WKN: A2DLP1). Unter diesem Link könnt ihr euch kostenlos für die Masterclass anmelden: https://form.jotform.com/Product_Unit/masterclass-boersenweisheiten. Wir freuen uns an Feedback über aaa@welt.de. Noch mehr "Alles auf Aktien" findet Ihr bei WELTplus und Apple Podcasts – inklusive aller Artikel der Hosts und AAA-Newsletter.[ Hier bei WELT.](https://www.welt.de/podcasts/alles-auf-aktien/plus247399208/Boersen-Podcast-AAA-Bonus-Folgen-Jede-Woche-noch-mehr-Antworten-auf-Eure-Boersen-Fragen.html.) [Hier] (https://open.spotify.com/playlist/6zxjyJpTMunyYCY6F7vHK1?si=8f6cTnkEQnmSrlMU8Vo6uQ) findest Du die Samstagsfolgen Klassiker-Playlist auf Spotify! Disclaimer: Die im Podcast besprochenen Aktien und Fonds stellen keine spezifischen Kauf- oder Anlage-Empfehlungen dar. Die Moderatoren und der Verlag haften nicht für etwaige Verluste, die aufgrund der Umsetzung der Gedanken oder Ideen entstehen. Hörtipps: Für alle, die noch mehr wissen wollen: Holger Zschäpitz können Sie jede Woche im Finanz- und Wirtschaftspodcast "Deffner&Zschäpitz" hören. +++ Werbung +++ Du möchtest mehr über unsere Werbepartner erfahren? [**Hier findest du alle Infos & Rabatte!**](https://linktr.ee/alles_auf_aktien) Impressum: https://www.welt.de/services/article7893735/Impressum.html Datenschutz: https://www.welt.de/services/article157550705/Datenschutzerklaerung-WELT-DIGITAL.html

APAC stocks traded mixed with the region indecisive amid light fresh catalysts and as participants digested earnings.House Democratic caucus will meet at noon Wednesday in Washington, according to Punchbowl's ShermanUK's Downing Street has launched an extraordinary operation to protect UK PM Starmer amid fears among the PM's closest allies that he is vulnerable to a leadership challenge in the wake of the Budget, according to The Guardian's Crerar.European equity futures indicate a positive cash market open with Euro Stoxx 50 futures up 0.3% after the cash market closed with gains of 1.1% on Tuesday.Looking ahead, highlights include German CPI Final (Oct), Italian Industrial Output (Sep), BoC Minutes (Oct), EIA STEO, OPEC MOMR, Speakers including ECB's Schnabel & de Guindos, Fed's Paulson, Bostic, Williams, Barr, Waller, Miran, Collins; US Treasury Secretary Bessent. Supply from Germany & US, Earnings from E On, Bayer, Infineon, ABN AMRO, Cisco & On.Read the full report covering Equities, Forex, Fixed Income, Commodites and more on Newsquawk

TODAY ON THE ROBERT SCOTT BELL SHOW: Legacy Media's Collapse, Sperm Crisis, Bayer Eyes Glyphosate Exit, Paxil Fraud Lawsuit, Vaccine Religion, Hava Levi, Hava Wellness, Natasha Trenev, Probiotics Pioneer, God Gap Closing and MORE! https://robertscottbell.com/legacy-medias-collapse-sperm-crisis-bayer-eyes-glyphosate-exit-paxil-fraud-lawsuit-vaccine-as-ritual-hava-levi-hava-wellness-natasha-trenev-probiotics-pioneer-god-gap-closing-and-m/https://boxcast.tv/view/legacy-media-collapse-bayer-eyes-glyphosate-exit-paxil-fraud-vaccine-religion-hava-levi-natasha-trenev---the-rsb-show-11-10-25-fpkyji8hgbz1vu05o9o3 Purpose and Character The use of copyrighted material on the website is for non-commercial, educational purposes, and is intended to provide benefit to the public through information, critique, teaching, scholarship, or research. Nature of Copyrighted Material Weensure that the copyrighted material used is for supplementary and illustrative purposes and that it contributes significantly to the user's understanding of the content in a non-detrimental way to the commercial value of the original content. Amount and Substantiality Our website uses only the necessary amount of copyrighted material to achieve the intended purpose and does not substitute for the original market of the copyrighted works. Effect on Market Value The use of copyrighted material on our website does not in any way diminish or affect the market value of the original work. We believe that our use constitutes a 'fair use' of any such copyrighted material as provided for in section 107 of the U.S. Copyright Law. If you believe that any content on the website violates your copyright, please contact us providing the necessary information, and we will take appropriate action to address your concern.

Dr. Pedro Barata and Dr. Aditya Bagrodia discuss the evolving landscape of testicular cancer survivorship, the impact of treatment-related complications, and management strategies to optimize long-term outcomes and quality of life. TRANSCRIPT:  Dr. Pedro Barata: Hello and welcome to By the Book, a podcast series from ASCO that features engaging conversations between editors and authors of the ASCO Educational Book. I'm Dr. Pedro Barata. I'm a medical oncologist at University Hospitals Seidman Cancer Center and associate professor of medicine at Case Western Reserve University in Cleveland, Ohio. I'm also an associate editor of the ASCO Educational Book. We all know that testicular cancer is a rare but highly curable malignancy that mainly affects young men. Multimodal advances in therapy have resulted in excellent cancer specific survival, but testicular cancer survivors face significant long term treatment related toxicities which affect their quality of life and require surveillance and management. With that, I'm very happy today to be joined by Dr. Aditya Bagrodia, a urologic oncologist, professor, and the GU Disease Team lead at UC San Diego[KI1]  Health, and also the lead author of the recently published paper in the ASCO Educational Book titled, "Key Updates in Testicular Cancer: Optimizing Survivorship and Survival." And he's also the host of the world-renowned BackTable Urology Podcast. Dr. Bagrodia, I'm so happy that you're joining us today. Welcome. Dr. Aditya Bagrodia: Thanks, Pedro. Absolutely a pleasure to be here. Really appreciate the opportunity. Dr. Pedro Barata: Absolutely.  So, just to say that our full disclosures are available in the transcript of this episode.  Let's get things started. I'm really excited to talk about this. I'm biased, I do treat testicular cancer among other GU malignancies and so it's a really, really important topic that we face every day, right? Fortunately, for most of these patients, we're able to cure them. But it always comes up the question, "What now? You know, scans, management, cardio oncology, what survivorship programs we have in place? Are we addressing the different survivorship piece, psychology, fertility, et cetera?" So, we'll try to capture all of that today. Aditya, congrats again, you did a fantastic job putting together the insights and thoughts and what we know today about this important topic. And so, let's get focused specifically about what happens when patients get cured. So, many of us, in many centers, were fortunate enough to have these survivorship programs together, but I find that sometimes from talking to colleagues, they're not exactly the same thing and they don't mean the same thing to different people, to different institutions, right? So, first things first. What do you tell a patient perhaps when they ask you, "What can happen to me now that I'm done with treatment for testicular cancer?" Whether it's chemotherapy or just surgery or even radiation therapy? "So, what about the long term? What should I expect, Doctor, that might happen to me in the long run?" Dr. Aditya Bagrodia: Totally. I mean, I think that question's really front and center, Pedro, and really appreciate you all highlighting this topic. It was an absolute honor to work with true thought leaders and the survivorship bit of it is front and center, in my opinion. It's really the focus, you know, we, generally speaking should be able to cure these young men, but it's the 10, 15, 20 years down the way that they're going to largely contend with. The conversation really begins at diagnosis, pre-education. Fortunately, the bulk of patients that present are those with stage one disease, and even very basic things like before orchiectomy, talking about a prosthetic; we know that that can impact body image and self esteem, whether or not they decide to receive it or not. Actually, just being offered a prosthetic is important and this is something, you know, for any urologist, it's kind of critical. To discussing fertility elements to this, taking your time to examine the contralateral testicle, ask about fertility problems, issues, concerns, offer sperm banking, even in the context of a completely normal contralateral testicle, I think these things are quite important.  So if it's somebody with stage one disease, you know, without going too far down discussing adjuvant therapy and so forth, I will start the conversation with, "You know, the testes do largely two things. They make testosterone and they make sperm." By and large, patients are going to be able to have acceptable levels of testosterone, adequate sperm parameters to maintain kind of a normal gonadal state and to naturally conceive, should that be something they're interested in. However, there's still going to be, depending on what resource you look at, somewhere in the order of 10-30% that are going to have issues. Where I think for the stage one patients, it's really incumbent upon us is actually to not wait for them to discuss their concerns, particularly with testosterone, which many times can be a little bit vague, but to proactively ask about it every time. Libido, erectile quality, muscle mass maintenance, energy, fatigue. All of these are kind of associated symptoms of hypogonadism. But for a lot of kids 18-20 years old, it's going to be something insidious that they don't think about. So, for the stage one patients, it absolutely starts with gonadal function. If they are stage two getting surgery, I think the counseling really needs to center around a possibility for ejaculatory dysfunction. Now, for a chemotherapy-naive, nerve-sparing RPLND, generally these days we should be able to preserve ejaculatory function at high volume centers, but you still want to bring that up and again kind of touch base on thinking about sperm banking and so forth before the operation, scars, those are things I think worth talking about, small risk of ascites. Then, I think the intensity of potential long term adverse effects really ramps up when we're talking about systemic therapy, chemotherapy. And then there's of course some radiation therapy specific elements that come up. So, for the chemotherapy bits of it, I really think this is going to be something that can be a complete multi-system affected intervention. So, anxiety, depression, our group has actually shown using some population resources that even suicidality can be increased among patients that have been treated for germ cell tumor. You know, really from the top down, tinnitus, hearing changes, those are things that we need to ask about at every appointment. Neuropathy, sexual health, that we kind of talked about, including ED (erectile dysfunction), vertigo, dizziness, Raynaud's phenomenon, these are kind of more the symptoms that I think we need to inquire about every time. And what we do here and I think at a lot of survivorship programs is use kind of a battery of validated instruments, germ cell tumor specific, platinum treated patient specific. So we use a combination of EORTC questions and PROMIS questions, which actually serves as like a review of systems for the patient, also as a research element. We review that and then depending on what might be going on, we can dig into that further, get them over to colleagues in audiology or psychology, et cetera.  And then of course, screening for the hypertension, hyperlipidemia, metabolic syndrome with basically you or myself or somebody kind of like us serving, many times it's the role of the PCP, just making sure we're checking out, you know, CBC, CMP, et cetera, lipid parameters to screen for those kind of cardiac associated issues along with secondary malignancies. Dr. Pedro Barata: So that's super comprehensive and thorough. Thank you so much. Actually, I love how you break it down in a simple way. Two functions of the testes, produce testosterone and then, you know, the problem related to that is the hypogonadism, and then the second, as you mentioned, produce sperm and of course related to the fertility issues with that.  So, let's start with the first one that you mentioned. So, you do cite that in your paper, around 5-10% of men end up getting, developing hypogonadism, maybe clinical when they present with symptoms, maybe subclinical. So, I'm wondering, for our audience, what kind of recommendations we would give for addressing that or kind of thinking of that? How often are you ordering those tests? And then, when you're thinking about testosterone replacement therapy, is that something you do immediately or are there any guidelines into context that? How do you approach that? Dr. Aditya Bagrodia: So, just a bit more on digging into it even in terms of the questions to ask, you know, "Do you have any decrease in sexual drive? Any erectile dysfunction? Are your morning erections still taking place? Has the ejaculate volume changed? Physically, muscle mass, strength? Have you been putting on weight? Have you noticed increase in body fat?" And sometimes this is complicated because there's some anxiety that comes along with a cancer diagnosis when you're 20, 30 years old, multifactorial, hair loss, hot flashes, irritability. Sometimes they'll, you know, literally they'll say, "You know, my significant other or partners noticed that I'm really just a little bit labile." So I think, you know, there's the symptoms and then checking, usually kind of a gonadal panel, FSH, LH, free and total testosterone, sex hormone binding globulin, that's going to be typically pretty comprehensive. So if you've got symptoms plus some laboratory work, and ideally that pre-orchiectomy testosterone gives you some delta. If they started out at an 800, 900, now they're 400, that might be a big change for them. And then, when you talk about TRT (Testosterone Replacement Therapy) recommendations, you know, Pedro, yourself, myself, we're kind of lucky to be at academic centers and we've got men's health colleagues that are ultra experts, but at a high level, I would say that a lot of the TRT options center around fertility goals. Exogenous testosterone treats the low T, but it does suppress gonadal function, including spermatogenesis. So if that's not a priority, they can just get TRT. It should be done under the care of a urologist, a men's health, an endocrinologist, where we're checking liver chemistries and CBCs and a PSA and so forth. If they're interested in fertility preservation, then I would say engaging an endocrinologist, men's health expert is important. There's medications even like hCG, Clomid, which works centrally and stimulate the gonadal access. Niche scenarios where they might want standard TRT now, and then down the way, 5, 7 years, they're thinking about coming off of that for fertility purposes, I think that's really where you want to have an expert involved because there's quite a bit of nuance there in recovery of actual spermatogenesis and so forth.  To kind of summarize, you got to ask about it. Checking it is, is not overly complicated. We do a baseline pre-orchiectomy and at least once annually, you can tag it in with the tumor markers, so it's not an extra blood draw. And if they have symptoms of course, kind of developed, then we'll move that up in the evaluation. Dr. Pedro Barata: Got it. And you also touch base on the fertility angle, which is truly important. And I'm just curious, you know, a lot of times many of us might see one, two patients a year, right, and we forget these protocols and what we've got to do about that.  And so I'm interested to hear your thoughts about when you think about fertility, and how proactive you get. In other words, who do you refer for the fertility clinic, for a fertility preservation program? You know, do all cases despite getting through orchiectomy or just the cases that you're going to, you know you're going to seek chemotherapy at some point? What kind of selection or it depends on the chemo, like how do you do that assessment about the referral for preservation program that you might have available at UCSD? Dr. Aditya Bagrodia: Yeah, I mean I feel really fortunate to sit on the NCCN Testis Cancer Guidelines. It's in there that fertility counseling should be discussed prior to orchiectomy. So 100% bring it up. If there are risk factors, undescended testicles, previous history of fertility concerns, atrophic contralateral testicle, anything on the ultrasound like microlithiasis in the contralateral testicle, you kind of wanna get it there. And then again, there's kind of niche scenarios where you're really worried, maybe get a semen analysis and it doesn't look that good, arrange for the time of orchiectomy to have onco-testicular sperm extraction from the, quote unquote, "normal" testis parenchyma. You know, I think you have to be kind of prepared to go that route and really make sure you're doing this completely comprehensively.  So pre-orchiectomy all patients. Don't really push for it too hard if they've got a contralateral testicle, if they've had no issues having children. There's some cost associated with this, sperm banking still isn't kind of covered even in the context of men with cancer. If they've got risk factors, absolutely pre-orchiectomy. Pre-RPLND, even though the rates of ejaculatory dysfunction at a high-volume center should be low single digits, I'll still offer it. That'd be a real catastrophe if they were in that small proportion of patients and now they're going to be reliant on things like intrauterine insemination, where it becomes quite expensive.  Pre-chemo, everybody. That's basically a standard these days where it should be discussed and it's kind of amazing currently, even if you don't have an accessible men's health fertility clinic, there are actually companies, I have no vested interest, Fellow is one such company where you can actually create an account, receive a FedEx semen analysis and cryopreservation kit, send it back in, and all CLIA certified, it's based out of California. The gentleman that runs it, is a urologist and very, very bright guy who's done a lot of great stuff for testis cancer. So, even for patients that are kind of in extremis at the hospital that kind of need to get going like yesterday, we still discuss it. We've got some mechanisms in place to either have them take a semen analysis over to our Men's Health clinic or send it off to Fellow, which I think is pretty cool and that even extends to some of our younger adolescent patients where going to a clinic and providing a sample might be tricky.  So, I think bringing it up every stage, anytime there's an intervention that might be offered, orchiectomy, chemo, surgery, radiation, it's kind of incumbent on us to discuss it. Dr. Pedro Barata: Gotcha. That's super helpful. And you also touch base on another angle, which is the psychosocial angle around this. You mentioned suicidal rates, you mentioned anxiety, perhaps depression in some cases as well as chronic fatigue, not necessarily just because of the low testosterone that you can get, but also from a psychological perspective. I'm curious, what do the recommendations look like for that? Do these patients need to see a social worker or a psychologist, or do they need to answer a screening test every time they come to see us and then based on that, we kind of escalate, take the next steps according to that? Do they see a psychologist perhaps every so often? How should that be managed and addressed? Dr. Aditya Bagrodia: It's an excellent question and again, these can be rather insidious symptoms where if you don't really dig in and inquire, they can be glossed over. I mean, how easy to say, "Your markers look okay, your scans look okay. See you in six months," and keep it kind of brief. First off, I think bringing it up proactively and normalizing it, that, "This may be something that you experience. Many people do, you're not alone, there's nothing kind of wrong with you." I also think that this is an area where support groups can be incredibly useful. We host the Testicular Cancer Awareness Foundation support group here. They'll talk about chemo brain or just like a little bit of an adjustment disorder after their diagnosis. Support groups, I think are critical. As I mentioned, we have a survivorship program that's led by a combination of our med oncs, myself on the uro-onc side, as well as APPs, where we are systematically asking about essentially the whole litany of issues that may arise, including psychosocial, anxiety, depression, suicidality. And we've got a nice kind of fast path into our cancer center support services for these young men to meet with a psychologist. If that isn't going to be sufficient, they can actually see a psychiatrist to discuss medications and so forth. I do think that we've got to screen for these because, as anticipated from diagnosis, those first 2 years, we see a rise. But even 10, 15 years out, we note, compared to controls, that there is an increased level of anxiety, depression, suicidality that might not just take place at that initial acute period of diagnosis and treatment. Dr. Pedro Barata: Really well said. Super important.  So I guess if I were to put all these together, with these really amazing advances in technology, we all know AI, some of us might be more or less aware of biomarkers coming up, including microRNA for example, and others, like as I think of all these potential long term complications for these patients, look at the future, I guess, can we use this as a way to deescalate treatment where it's not really necessary, as a way to actually prevent some of these complications? Like, how do we see where we're heading? As we manage testicular cancer, let's say, within the next 5 or 10 years, do you think there's something coming up that's going to be different from what we're doing things today? Dr. Aditya Bagrodia: Totally. I mean, I think it's as exciting as a time as there's ever been, you know, maybe notwithstanding circa 1970s when platinum was discovered. So microRNAs, which you mentioned, you know, there's a new candidate biomarker, microRNA-371. We are super excited here at UCSD. We actually have it CLIA-certified available in our lab and are ordering these tests for patients kind of in their acute stage, you know, stage one and surveillance, stage two, post-RPLND, receiving chemotherapy. And essentially this is a universal germ cell tumor specific biomarker, except for teratoma, suffice it to say 90% sensitive and specific. And I think it's going to change the way that we diagnose and manage patients. You know, pre-orchiectomy, that's pretty straightforward. Post-orchiectomy, maybe we can really decrease the number of CT scans that are done. Maybe we can identify those patients that basically have occult disease where we can intervene early, either with RPLND or single cycle chemo. Post-RPLND, identify the patients who are at higher risk of relapse that may benefit from some adjuvant therapy. In the advanced setting, look at marker decline for patients in addition to standard tumor markers. Can we modulate their systemic therapy?  So, the international interest is largely on modifying things. There's really cool clinical trials that we have for stage one patients, that treatment would be prescribed based on a post-orchiectomy microRNA. I think the microRNAs are really exciting. Teratoma remains an outstanding question. I think this is where maybe ctDNA, perhaps some radiomics and advanced imaging processing and incorporating AI may allow us to safely avoid a lot of these post-chemo RPLNDs. And then identification using SNPs and so forth of who might be most susceptible to some of the cardiac toxicity, autotoxicity and personalizing things in that way as well. Dr. Pedro Barata: Super exciting, right, what's about to come? And I agree with you, I think it's going to change dramatically how we manage this disease.  This has been a pleasure sitting down with you. I guess before letting you go, anything else you'd like to add before we wrap it up? Dr. Aditya Bagrodia: Yeah, first off, again, just want to thank you and ASCO for the opportunity. And it's easy enough to, I think, approach a patient with the testicular germ cell tumor as, "This is an easy case. We're just going to do whatever we've done. Go to the guidelines that says do X, Y, or Z." But there's so much more nuance to it than that. Getting it done perfectly, I think, is mandatory. Whatever we do is an impact on them for the next 50, 60, 70 years of their life. And I found the germ cell tumor community, people are really passionate about it. If you're ever uncertain, there's experts throughout the country and internationally. Ask somebody before you do something that you can't undo. I think we owe it to them to get it perfect so that we can really maximize the survivorship and the survival like we've been talking about. Dr. Pedro Barata: Aditya, thanks for sharing your fantastic insights with us on this podcast. Dr. Aditya Bagrodia: All right, Pedro. Fantastic. Appreciate the opportunity. Dr. Pedro Barata: And also, thank you to our listeners for your time today. I actually encourage you to check out Dr. Bagrodia's article in the 2025 ASCO Educational Book. We'll post a link to the paper in the show notes. Remember, it's free access online, and you can actually download it as well as a PDF. You can also find on the website a wealth of other great papers from the ASCO Educational Book on key advances and novel approaches that are shaping modern oncology.  So with that, thank you everyone. Thank you, Aditya, one more time, for joining us. Thank you, have a good day. Disclaimer: The purpose of this podcast is to educate and to inform. This is not a substitute for professional medical care and is not intended for use in the diagnosis or treatment of individual conditions. Guests on this podcast express their own opinions, experience, and conclusions. Guest statements on the podcast do not express the opinions of ASCO. The mention of any product, service, organization, activity, or therapy should not be construed as an ASCO endorsement. Follow today's speakers:         Dr. Pedro Barata  @PBarataMD   Dr. Aditya Bagrodia @AdityaBagrodia Follow ASCO on social media:         @ASCO on X (formerly Twitter)         ASCO on Bluesky        ASCO on Facebook         ASCO on LinkedIn         Disclosures:      Dr. Pedro Barata:  Stock and Other Ownership Interests: Luminate Medical  Honoraria: UroToday  Consulting or Advisory Role: Bayer, BMS, Pfizer, EMD Serono, Eisai, Caris Life Sciences, AstraZeneca, Exelixis, AVEO, Merck, Ipson, Astellas Medivation, Novartis, Dendreon  Speakers' Bureau: AstraZeneca, Merck, Caris Life Sciences, Bayer, Pfizer/Astellas  Research Funding (Inst.): Exelixis, Blue Earth, AVEO, Pfizer, Merck   Dr. Aditya Bagrodia: Consulting or Advisory Role: Veracyte, Ferring  

Broadcast from KSQD, Santa Cruz on 11-06-2025:>/p> Dr. Dawn interviews Cindy Jackonette and Dr. Michael Alexander about a fundraiser for pancreatic cancer awareness on November 15th at Bargetto Winery from 2-5pm, supporting the Santa Cruz Cancer Benefit Group. Dr. Alexander explains pancreatic cancer has only 10-15% five-year survival rates and is difficult to screen for. Screening involves complex endoscopy procedures examining pancreatic ducts, CT scans and biomarker scans. The disease represents 3% of cancer cases but 8% of deaths. Immune checkpoint inhibitors show limited success except in Lynch syndrome patients with DNA repair defects. The Santa Cruz Cancer Benefit Group donates annually to local cancer organizations and is all volunteer-run with minimal overhead. An emailer asks when her 56-year-old half-African American son should get colon cancer screening given his father and uncle both had the disease. Dr. Dawn explains African Americans have increased risk and recommends immediate colonoscopy despite the ideal screening window being 10 years ago. She emphasizes identifying whether he produces polyps, which would require surveillance every 3-5 years. Unlike pancreatic cancer, colon cancer is highly curable when detected early, with death rates dropping 30-40% since colonoscopies became standard in the mid-1990s. She recommends preventive measures including daily 200mg ibuprofen (if no ulcer history) and a high-fiber diet rich in colorful vegetables containing antioxidants that reduce oxidative stress and DNA damage from free radicals. An emailer from Israel asks about supporting his 38-year-old son's rectal adenocarcinoma treatment. Dr. Dawn recommends nutritional strategies including juicing 10 different fruits and vegetables daily, 20mg melatonin for synergy with chemotherapy, vitamin D supplementation, and L-glutamine as primary food for bowel healing and lymphocyte function. She suggests DHA fish oil to enhance chemotherapy effectiveness, green tea for oncogene inhibition, astragalus herb to increase phagocytic activity and natural killer cells, and rotating water-extracted mushroom formulas with beta-glucans, particularly maitake and shitake. Glutamine also protects mucous membranes from radiation burns. Dr. Dawn discusses alarming cancer rate increases among young adults in Corn Belt states including Iowa, Nebraska, Illinois, Minnesota, Indiana, and Kansas. Since 2015, these states show 5% higher cancer rates for ages 15-49 compared to national averages, with particularly elevated kidney and skin cancer rates. Young women face 66% higher skin cancer risk than peers in other states. . Governor Kim Reynolds invested $1 million for research while Bayer's attempt to shield Roundup from lawsuits failed. Dr. Dawn notes Roundup now contains diquat after removing glyphosate. It has taken decades to accumulate evidence of glyphosates harms, She warns that absence of evidence of Diquats being harmful isn't evidence of safety and that Ames testing suggests high mutation potential. An emailer shares a JAMA article on lithium for Alzheimer's disease. Dr. Dawn explains that calcium dysregulation through NMDA receptors plays an upstream role in Alzheimer's pathology. Lithium, a bipolar disorder treatment, can reset deranged calcium gates, inhibiting mitochondrial damage and tau protein production. She emphasizes tau protein as the true culprit in Alzheimer's while amyloid beta is more symptomatic. Correcting calcium homeostasis allows neuronal autophagy systems to clear waste more efficiently rather than being overwhelmed. She reports dramatic peanut allergy declines following 2017 pediatric recommendations for introducing peanuts at 4-6 months based on the LEAP study showing 81% reduction. Between 2017-2020, peanut allergies dropped from 0.79% to 0.45% of all children under 3, with overall food allergies declining 36%. Studies also show pregnant mothers eating peanuts reduces offspring allergy risk by promoting immune tolerance. We conclude with breakthrough wireless retinal implants for macular degeneration, where cameras on glasses convert images to near-infrared signals to retinal implants which stimulate surviving retinal neurons. The prototype allowed patients to improve by two lines on eye charts and perceive facial expressions and read smaller print.